<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD005289.pub3" GROUP_ID="MENSTR" ID="306104022819272034" MERGED_FROM="" MODIFIED="2014-08-13 04:50:41 +0100" MODIFIED_BY="Helen Nagels" NOTES="&lt;p&gt;Exported from Review Manager 4.2.8&lt;br&gt;Exported from Review Manager 4.3.1&lt;br&gt;Exported from Review Manager 4.2.8&lt;br&gt;Exported from Review Manager 4.2.10&lt;br&gt;Exported from Review Manager 4.2.9&lt;br&gt;Exported from Review Manager 4.2.6&lt;br&gt;Exported from Review Manager 4.2.4&lt;br&gt;Exported from Review Manager 4.2.3&lt;br&gt;Exported from Review Manager 4.2.4&lt;br&gt;Exported from Review Manager 4.2.3&lt;br&gt;&lt;/p&gt;" NOTES_MODIFIED="2014-08-07 10:39:23 +1200" NOTES_MODIFIED_BY="Helen E Nagels" REVIEW_NO="IOK972" REVMAN_SUB_VERSION="5.3.3 " REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="5.0">
<COVER_SHEET MODIFIED="2014-08-13 04:50:41 +0100" MODIFIED_BY="Helen Nagels">
<TITLE>Monitoring of stimulated cycles in assisted reproduction (IVF and ICSI)</TITLE>
<CONTACT MODIFIED="2014-08-13 04:50:41 +0100" MODIFIED_BY="Helen Nagels"><PERSON ID="14428" ROLE="AUTHOR"><PREFIX>Ms</PREFIX><FIRST_NAME>Irene</FIRST_NAME><LAST_NAME>Kwan</LAST_NAME><POSITION>Research Officer</POSITION><EMAIL_1>I.Kwan@ioe.ac.uk</EMAIL_1><EMAIL_2>irenekwan27@gmail.com</EMAIL_2><ADDRESS><DEPARTMENT>Evidence for Policy and Practice Information and Coordinating Centre (EPPI-Centre), Social Science Research Unit (SSRU)</DEPARTMENT><ORGANISATION>Institute of Education, University of London</ORGANISATION><ADDRESS_1>10 Woburn Square</ADDRESS_1><CITY>London</CITY><ZIP>WC1H 0NR</ZIP><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>44 (0) 20 7612 6613</PHONE_1><FAX_1>+44 (0) 20 7612 6400</FAX_1></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2014-08-13 04:50:41 +0100" MODIFIED_BY="Helen Nagels"><PERSON ID="14428" ROLE="AUTHOR"><PREFIX>Ms</PREFIX><FIRST_NAME>Irene</FIRST_NAME><LAST_NAME>Kwan</LAST_NAME><POSITION>Research Officer</POSITION><EMAIL_1>I.Kwan@ioe.ac.uk</EMAIL_1><EMAIL_2>irenekwan27@gmail.com</EMAIL_2><ADDRESS><DEPARTMENT>Evidence for Policy and Practice Information and Coordinating Centre (EPPI-Centre), Social Science Research Unit (SSRU)</DEPARTMENT><ORGANISATION>Institute of Education, University of London</ORGANISATION><ADDRESS_1>10 Woburn Square</ADDRESS_1><CITY>London</CITY><ZIP>WC1H 0NR</ZIP><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>44 (0) 20 7612 6613</PHONE_1><FAX_1>+44 (0) 20 7612 6400</FAX_1></ADDRESS></PERSON><PERSON ID="18315" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Siladitya</FIRST_NAME><LAST_NAME>Bhattacharya</LAST_NAME><EMAIL_1>s.bhattacharya@abdn.ac.uk</EMAIL_1><ADDRESS><DEPARTMENT>Obstetrics and Gynaecology</DEPARTMENT><ORGANISATION>Aberdeen Maternity Hospital</ORGANISATION><ADDRESS_2>Foresterhill</ADDRESS_2><CITY>Aberdeen</CITY><ZIP>AB9 2ZD</ZIP><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>+44 1224 681 818</PHONE_1><FAX_1>+44 1224 684 880</FAX_1></ADDRESS></PERSON><PERSON ID="z1211290249087218987627620511391" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Angela</FIRST_NAME><LAST_NAME>Kang</LAST_NAME><POSITION>ITP trainee</POSITION><EMAIL_1>amk.kang@gmail.com</EMAIL_1><EMAIL_2>amk.kang@gmail.com</EMAIL_2><MOBILE_PHONE>+64210363825</MOBILE_PHONE><ADDRESS><ORGANISATION>Counties Manukau District Health Board</ORGANISATION><CITY>Auckland</CITY><COUNTRY CODE="NZ">New Zealand</COUNTRY></ADDRESS></PERSON><PERSON ID="z1301151555239322014256390740810" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Andrea</FIRST_NAME><LAST_NAME>Woolner</LAST_NAME><POSITION>Clinical Lecturer in Obstetrics and Gynaecology</POSITION><EMAIL_1>a.woolner@abdn.ac.uk</EMAIL_1><ADDRESS><DEPARTMENT>Division of Applied Health Sciences</DEPARTMENT><ORGANISATION>University of Aberdeen, Aberdeen Maternity Hospital</ORGANISATION><CITY>Aberdeen</CITY><ZIP>AB9 2ZD</ZIP><COUNTRY CODE="GB">UK</COUNTRY></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2014-08-01 13:51:44 +1200" MODIFIED_BY="Helen E Nagels">
<UP_TO_DATE>
<DATE DAY="30" MONTH="5" YEAR="2014"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="30" MONTH="5" YEAR="2014"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="30" MONTH="5" YEAR="2016"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="2" YEAR="2005"/>
<REVIEW_PUBLISHED ISSUE="2" YEAR="2008"/>
<LAST_CITATION_ISSUE ISSUE="8" YEAR="2014"/>
</DATES>
<WHATS_NEW MODIFIED="2014-07-05 18:54:33 +1200" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_OLD_CONCLUSIONS" MODIFIED="2014-07-05 18:54:27 +1200" MODIFIED_BY="[Empty name]">
<DATE DAY="30" MONTH="5" YEAR="2014"/>
<DESCRIPTION>
<P>New studies included and summary of findings table added.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2014-07-05 18:54:33 +1200" MODIFIED_BY="[Empty name]">
<DATE DAY="30" MONTH="5" YEAR="2014"/>
<DESCRIPTION>
<P>Four studies added to the review (<LINK REF="STD-Aguirre-2010" TYPE="STUDY">Aguirre 2010</LINK>; <LINK REF="STD-Rongieres-2006" TYPE="STUDY">Rongieres 2006</LINK>; <LINK REF="STD-Strawn-2007" TYPE="STUDY">Strawn 2007</LINK>; <LINK REF="STD-Wiser-2012" TYPE="STUDY">Wiser 2012</LINK>).</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2013-12-16 12:15:28 +1300" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS" MODIFIED="2013-12-16 12:15:28 +1300" MODIFIED_BY="Irene OL Kwan">
<DATE DAY="15" MONTH="12" YEAR="2013"/>
<DESCRIPTION>
<P>Substantive amendment</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2013-12-02 07:02:19 +1300" MODIFIED_BY="[Empty name]">
<DATE DAY="7" MONTH="11" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT MODIFIED="2014-06-25 07:15:28 +1200" MODIFIED_BY="Irene OL Kwan">
<INTERNAL_SOURCES MODIFIED="2014-06-25 07:15:28 +1200" MODIFIED_BY="[Empty name]">
<SOURCE MODIFIED="2014-06-25 07:15:28 +1200" MODIFIED_BY="[Empty name]">
<NAME>Review authors</NAME>
<COUNTRY CODE="NONE">Other</COUNTRY>
<DESCRIPTION>
<P>The review authors had no specific funding for this review</P>
</DESCRIPTION>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES MODIFIED="2014-01-08 12:44:45 +1300" MODIFIED_BY="[Empty name]">
<SOURCE MODIFIED="2014-01-08 12:44:45 +1300" MODIFIED_BY="[Empty name]">
<NAME>None</NAME>
<COUNTRY CODE="NONE">Other</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2014-08-07 10:35:14 +1200" MODIFIED_BY="Helen E Nagels">
<SUMMARY MODIFIED="2014-08-07 10:35:14 +1200" MODIFIED_BY="Helen E Nagels">
<TITLE MODIFIED="2014-01-12 06:46:16 +1300" MODIFIED_BY="Andrea MF Woolner ">Monitoring of stimulated cycles in fertility treatment involving in vitro fertilisation (IVF) and intra-cytoplasmic sperm injection (ICSI)</TITLE>
<SUMMARY_BODY MODIFIED="2014-08-07 10:35:14 +1200" MODIFIED_BY="Helen E Nagels">
<P>Review question: can ultrasound alone be used safely without adding estradiol blood test measurements to monitor women undergoing controlled ovarian hyperstimulation during IVF and ICSI? We reviewed the evidence on monitoring women undergoing controlled ovarian hyperstimulation as part of IVF or ICSI by transvaginal ultrasound (TVUS) only versus traditional combined monitoring (TVUS) and blood hormone (estradiol) levels.</P>
<P>Background: assisted reproduction techniques such as IVF and ICSI involve ovarian hyperstimulation. The ovaries are artificially stimulated to produce follicles and then ovulation (release of a mature ovum or egg) is induced so that eggs can be retrieved for use in either IVF or ICSI to produce embryos in the laboratory. Traditionally women undergoing controlled ovarian hyperstimulation prior to ovulation induction have been monitored by TVUS and measurement of the hormone estradiol level in their blood. The aim of monitoring is to detect the optimum time to induce ovulation (by the administration of human chorionic gonadotrophin or luteinising hormone) and to determine an adequate response to ovarian hyperstimulation to allow egg retrieval, but importantly also to identify women at risk of the potentially serious rare condition of ovarian hyperstimulation syndrome (OHSS). It has been suggested that a simplified protocol of monitoring by TVUS alone may reduce unnecessary anxiety and operational costs during IVF and ICSI.</P>
<P>Study characteristics: we included six randomised controlled trials conducted in the UK, France, Spain, Israel and the US, including 781 women. They compared monitoring with TVUS only versus TVUS plus serum estradiol concentration in women undergoing ovarian hyperstimulation for IVF and ICSI treatment. The evidence was current to May 2014.</P>
<P>Key results: none of the six studies reported our primary outcome of live birth rate. Pooled data showed no evidence of a difference in clinical pregnancy rate between monitoring with TVUS only and monitoring with TVUS plus estradiol measurement (odds ratio (OR) 1.10; 95% CI 0.79 to 1.54; four studies; N = 617; I² = 5%; low quality evidence). Our findings suggest that compared with women with a 34% chance of clinical pregnancy using monitoring with TVUS plus serum estradiol, the clinical pregnancy rate in women using TVUS only was between 29% and 44%. There was no evidence of a difference in<I> </I>OHSS between the two arms (OR 1.03; 95% CI 0.48 to 2.20; six studies; N = 781; I² = 0%; low quality evidence), suggesting that compared with women with a 4% chance of OHSS using monitoring with TVUS plus serum estradiol, the OHSS rate in women monitored by TVUS only was between 2% and 8%.</P>
<P>Quality of the evidence: the evidence was of low quality. Limitations included imprecision and potential bias due to unclear randomisation methods, allocation concealment and blinding, as well as differences in the treatment protocols. Quality assessment was hampered by a lack of methodological descriptions in several studies. Two studies reported funding by pharmaceutical companies, whereas the remaining four studies did not report their sources of funding.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2014-07-18 17:07:32 +1200" MODIFIED_BY="Helen E Nagels">
<ABS_BACKGROUND MODIFIED="2014-07-05 18:55:40 +1200" MODIFIED_BY="[Empty name]">
<P>Traditional monitoring of ovarian hyperstimulation during in vitro fertilisation (IVF) and intra-cytoplasmic sperm injection (ICSI) treatment has included transvaginal ultrasonography (TVUS) plus serum estradiol levels to ensure safe practice by reducing the incidence and severity of ovarian hyperstimulation syndrome (OHSS) whilst achieving the good ovarian response needed for assisted reproduction treatment. The need for combined monitoring (using TVUS and serum estradiol) during ovarian stimulation in assisted reproduction is controversial. It has been suggested that combined monitoring is time consuming, expensive and inconvenient for women and that simplification of IVF and ICSI therapy by using TVUS only should be considered.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2014-07-05 19:32:46 +1200" MODIFIED_BY="[Empty name]">
<P>To assess the effect of monitoring controlled ovarian hyperstimulation (COH) in IVF and ICSI cycles in subfertile couples with TVUS only versus TVUS plus serum estradiol concentration, with respect to rates of live birth, pregnancy and OHSS.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2014-07-05 18:57:25 +1200" MODIFIED_BY="[Empty name]">
<P>We searched the Menstrual Disorders and Subfertility Group Specialised Register of controlled trials, the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, EMBASE, CINAHL, PsycINFO, the National Research Register, and web-based trial registers such as Current Controlled Trials. The last search was conducted in May 2014. There was no language restriction applied. All references in the identified trials and background papers were checked and authors were contacted to identify relevant published and unpublished data.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2014-07-05 18:58:11 +1200" MODIFIED_BY="[Empty name]">
<P>Only randomised controlled trials that compared monitoring with TVUS only versus TVUS plus serum estradiol concentrations in women undergoing COH for IVF and ICSI treatment were included.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2014-07-05 18:58:36 +1200" MODIFIED_BY="[Empty name]">
<P>Three review authors independently selected the studies, extracted data and assessed risk of bias. They resolved disagreements by discussion with the rest of the authors. Outcomes data were pooled and summary statistics were presented when appropriate. The quality of the evidence was rated using the GRADE methods.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2014-07-18 17:07:32 +1200" MODIFIED_BY="Helen E Nagels">
<P>With this update, four new studies were identified resulting in a total of six trials including 781 women undergoing monitoring of COH with either TVUS alone or a combination of TVUS and serum estradiol concentration during IVF or ICSI treatment.</P>
<P>None of the six studies reported our primary outcome of live birth rate. Pooled data showed no evidence of a difference in clinical pregnancy rate per woman between monitoring with TVUS only and combined monitoring (odds ratio (OR) 1.10; 95% confidence interval (CI) 0.79 to 1.54; four studies; N = 617; I² = 5%; low quality evidence). This suggests that compared with women with a 34% chance of clinical pregnancy using monitoring with TVUS plus serum estradiol, the clinical pregnancy rate in women using TVUS only was between 29% and 44%.</P>
<P>There was no evidence of a difference between the groups in the reported cases of OHSS (OR 1.03; 95% CI 0.48 to 2.20; six studies; N = 781; I² = 0%; low quality evidence), suggesting that compared with women with a 4% chance of OHSS using monitoring with TVUS plus serum estradiol, the OHSS rate in women monitored by TVUSS only was between 2% and 8%.</P>
<P>There was no evidence of a difference between the groups in the mean number of oocytes retrieved pre woman (mean difference (MD) 0.32; 95% CI -0.60 to 1.24; five studies; N = 596; I² = 17%; low quality evidence).</P>
<P>The evidence was low quality for all comparisons. Limitations included imprecision and potential bias due to unclear randomisation methods, allocation concealment and blinding, as well as differences in treatment protocols. Quality assessment was hampered by the lack of methodological descriptions in several studies.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2014-07-05 19:05:47 +1200" MODIFIED_BY="[Empty name]">
<P>This review update found no evidence from randomised trials to suggest that combined monitoring by TVUS and serum estradiol is more efficacious than monitoring by TVUS alone with regard to clinical pregnancy rates and the incidence of OHSS. The number of oocytes retrieved appeared similar for both monitoring protocols. The data suggest that both these monitoring methods are safe and reliable. However, these results should be interpreted with caution because the overall quality of the evidence was low. Results were compromised by imprecision and poor reporting of study methodology. A combined monitoring protocol including both TVUS and serum estradiol may need to be retained as precautionary good clinical practice and as a confirmatory test in a subset of women to identify those at high risk of OHSS. An economic evaluation of the costs involved with the two methods and the views of the women undergoing cycle monitoring would be welcome.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2014-08-06 17:19:26 +1200" MODIFIED_BY="Helen E Nagels">
<BACKGROUND MODIFIED="2014-07-05 19:31:22 +1200" MODIFIED_BY="[Empty name]">
<P>The overall aim of in vitro fertilisation (IVF) and intra-cytoplasmic sperm injection (ICSI) in assisted reproduction is to achieve pregnancy and ultimately live births. A successful outcome from IVF and ICSI is dependent upon a preliminary phase of controlled ovarian hyperstimulation (COH) using exogenous gonadotrophins. The aim of COH is to produce multiple follicles and thereafter to induce follicle maturation. Ovulation is then induced by administration of human chorionic gonadotrophin (hCG) or luteinizing hormone, which then allows optimal and multiple opportunities for subsequent fertilisation. However, during this process of COH and induction there exists the risk of ovarian hyperstimulation syndrome (OHSS), which is the most serious iatrogenic complication of ovarian stimulation. There is debate over whether women should be monitored during COH using a combination of transvaginal ultrasound (TVUS) and serum estradiol measurements or by TVUS alone.</P>
<CONDITION MODIFIED="2014-07-05 19:22:52 +1200" MODIFIED_BY="[Empty name]">
<P>The aim of achieving clinical pregnancy and ultimately live births must be balanced with the risks associated with assisted reproductive techniques, and specifically those related to ovarian hyperstimulation. OHSS is a systemic condition associated with development of a large number of follicles and is a potentially fatal condition (<LINK REF="REF-Delvigne-2002" TYPE="REFERENCE">Delvigne 2002</LINK>; <LINK REF="REF-Jenkins-2006" TYPE="REFERENCE">Jenkins 2006</LINK>; <LINK REF="REF-Schenker-1978" TYPE="REFERENCE">Schenker 1978</LINK>). OHSS can lead to ascites, pleural and pericardial effusion, haemoconcentration, venous thromboembolism, hepatorenal failure and coagulopathy (<LINK REF="REF-Borase-2012" TYPE="REFERENCE">Borase 2012</LINK>; <LINK REF="REF-Delvigne-2002" TYPE="REFERENCE">Delvigne 2002</LINK>; <LINK REF="REF-Jenkins-2006" TYPE="REFERENCE">Jenkins 2006</LINK>; <LINK REF="REF-Schenker-1978" TYPE="REFERENCE">Schenker 1978</LINK>). It has been suggested that the condition is related to the release of vasoactive chemicals from the ovaries during COH and ovulation induction, which leads to increased vascular permeability and thus fluid shifts extravascularly (<LINK REF="REF-Jenkins-2006" TYPE="REFERENCE">Jenkins 2006</LINK>). However, the exact aetiology remains unknown. The incidence of OHSS is estimated to range from 0.2% to 2.7% of all assisted reproductive cycles, including intra-uterine insemination (<LINK REF="REF-Asch-1991" TYPE="REFERENCE">Asch 1991</LINK>; <LINK REF="REF-Ferraretti-2012" TYPE="REFERENCE">Ferraretti 2012</LINK>; <LINK REF="REF-MacDougall-1992" TYPE="REFERENCE">MacDougall 1992</LINK>; <LINK REF="REF-Nygren-2002" TYPE="REFERENCE">Nygren 2002</LINK>; <LINK REF="REF-Roest-1996" TYPE="REFERENCE">Roest 1996</LINK>; <LINK REF="REF-Smitz-1990" TYPE="REFERENCE">Smitz 1990</LINK>).</P>
</CONDITION>
<INTERVENTION MODIFIED="2014-07-05 19:25:08 +1200" MODIFIED_BY="[Empty name]">
<P>COH is monitored by means of TVUS in order to gain information on the number and size of developing follicles and to determine the optimal time for hCG administration prior to oocyte retrieval. Some fertility units measure serum estradiol concentration alongside TVUS during the course of COH to provide added information about the ovarian response and the potential risk of hyperstimulation. Combined monitoring with TVUS and serum estradiol concentrations has been suggested to be the gold standard for monitoring stimulated cycles in IVF and ICSI procedures (<LINK REF="REF-Rizk-1992" TYPE="REFERENCE">Rizk 1992</LINK>).</P>
</INTERVENTION>
<THEORY MODIFIED="2014-07-05 19:30:02 +1200" MODIFIED_BY="[Empty name]">
<P>The number and size of follicles visualised at TVUS provide an estimate of ovarian response and hCG is used to trigger ovulation when a certain number of follicles reach a certain size. Estradiol, which is produced by developing follicles, provides additional information which is believed to further improve the decision making process; follicle maturity is supported by adequate estradiol levels while there is an increased risk of OHSS in the presence of very high levels. The overall aim is to ensure optimal stimulation of the ovaries and to reduce the incidence and severity of OHSS whilst obtaining a successful treatment outcome.</P>
<P>TVUS monitoring alone has been reported to provide more accurate information on follicular number and size than can be obtained by serum estradiol concentration alone in women with anovulatory infertility undergoing gonadotrophin induction therapy (<LINK REF="REF-Haning-1982" TYPE="REFERENCE">Haning 1982</LINK>; <LINK REF="REF-Hardiman-1990" TYPE="REFERENCE">Hardiman 1990</LINK>; <LINK REF="REF-Shoham-1991" TYPE="REFERENCE">Shoham 1991</LINK>).</P>
<P>A cohort study comparing TVUS only versus TVUS plus hormonal determinations, including serum estradiol concentrations, for ovarian monitoring in women undergoing IVF reported no differences in live birth rate and the incidence of OHSS, and there was a significant economic benefit in the TVUS only monitoring protocol (<LINK REF="REF-Murad-1998" TYPE="REFERENCE">Murad 1998</LINK>). Another cohort study reported that TVUS alone, performed during COH in IVF and intra-uterine insemination, predicted 88% of cycle decisions as compared to 100% of cycle decisions that were predicted using combined monitoring (<LINK REF="REF-Confino-1996" TYPE="REFERENCE">Confino 1996</LINK>).</P>
<P>One non-randomised study reported no differences in IVF outcomes and incidence of OHSS between women whose ovarian response was monitored by TVUS and serum estradiol concentration on the day of human chorionic gonadotrophin (hCG) administration and women who were monitored with TVUS only and had the serum estradiol concentration checked if the risk of OHSS was deemed to be high (<LINK REF="REF-Thomas-2002" TYPE="REFERENCE">Thomas 2002</LINK>). A more recent non-randomised study compared combined monitoring with ultrasound monitoring only in women undergoing IVF and ICSI and reported equivalence in results between the two arms for the primary outcome of number of mature oocytes at egg retrieval (<LINK REF="REF-Vandekerckhove-2014" TYPE="REFERENCE">Vandekerckhove 2014</LINK>).</P>
</THEORY>
<IMPORTANCE MODIFIED="2014-07-05 19:31:22 +1200" MODIFIED_BY="[Empty name]">
<P>The need for combined monitoring during COH in IVF and ICSI is controversial. It has been suggested that close monitoring is time consuming, expensive and inconvenient for the woman (<LINK REF="REF-Howard-1988" TYPE="REFERENCE">Howard 1988</LINK>; <LINK REF="REF-Rainhorn-1987" TYPE="REFERENCE">Rainhorn 1987</LINK>; <LINK REF="REF-Tan-1992" TYPE="REFERENCE">Tan 1992</LINK>). Simplification of IVF therapy by minimal monitoring has been reported to have no adverse effects on treatment outcome and the incidence of OHSS (<LINK REF="REF-Abdalla-1989" TYPE="REFERENCE">Abdalla 1989</LINK>; <LINK REF="REF-Roest-1995" TYPE="REFERENCE">Roest 1995</LINK>; <LINK REF="REF-Tan-1994" TYPE="REFERENCE">Tan 1994</LINK>) and some IVF programs have abandoned the use of the hormone assay completely (<LINK REF="REF-Kemeter-1989" TYPE="REFERENCE">Kemeter 1989</LINK>; <LINK REF="REF-Tan-1994" TYPE="REFERENCE">Tan 1994</LINK>; <LINK REF="REF-Vlaisavljevic-1992" TYPE="REFERENCE">Vlaisavljevic 1992</LINK>). This review is important to couples, clinicians and researchers because if there is evidence that estradiol measurements are unnecessary, hospitals and clinics could change their protocols thus reducing associated costs and anxiety to the couple undergoing IVF or ICSI.</P>
</IMPORTANCE>
</BACKGROUND>
<OBJECTIVES MODIFIED="2014-07-05 19:32:36 +1200" MODIFIED_BY="[Empty name]">
<P>To assess the effect of monitoring controlled ovarian hyperstimulation (COH) in IVF and ICSI cycles in subfertile couples with TVUS only versus TVUS plus serum estradiol concentration, with respect to rates of live birth, pregnancy and OHSS.<B>
<BR/>
</B>
</P>
</OBJECTIVES>
<METHODS MODIFIED="2014-07-18 17:09:45 +1200" MODIFIED_BY="Helen E Nagels">
<SELECTION_CRITERIA MODIFIED="2014-07-05 19:38:06 +1200" MODIFIED_BY="[Empty name]">
<CRIT_STUDIES MODIFIED="2014-07-05 19:36:19 +1200" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trials only. Quasi-randomised trials were excluded. Cross-over trials were excluded as they are an inappropriate design for this question because &#8216;success&#8217; in the first phase would prevent entry to subsequent phases of the study.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2014-07-05 19:36:29 +1200" MODIFIED_BY="[Empty name]">
<P>All women undergoing COH with gonadotrophins in IVF and ICSI procedures.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2014-03-16 04:31:25 +1300" MODIFIED_BY="Kwan I ">
<P>Monitoring by transvaginal ultrasound (TVUS) only versus combined monitoring with TVUS plus serum estradiol concentrations.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2014-07-05 19:38:06 +1200" MODIFIED_BY="[Empty name]">
<CRIT_OUTCOMES_PRIMARY MODIFIED="2014-06-24 20:19:05 +1200" MODIFIED_BY="Kwan I ">
<P>Live birth rate per woman</P>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2014-07-05 19:38:06 +1200" MODIFIED_BY="[Empty name]">
<OL>
<LI>Pregnancy rate and multiple pregnancy rate per woman, where clinical pregnancy is defined as a pregnancy diagnosed by ultrasonographic visualisation of one or more gestational sacs or definitive clinical signs of pregnancy. It includes ectopic pregnancy. Multiple gestational sacs are counted as one clinical pregnancy</LI>
<LI>Number of oocytes recovered per woman</LI>
<LI>Adverse outcomes: rate of ovarian hyperstimulation syndrome (OHSS) per woman; number of cancelled cycles per woman</LI>
<LI>Costs of monitoring with TVUS versus costs of monitoring with TVUS plus serum estradiol concentrations</LI>
</OL>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2014-07-18 17:04:26 +1200" MODIFIED_BY="Helen E Nagels">
<ELECTRONIC_SEARCHES MODIFIED="2014-07-05 19:40:30 +1200" MODIFIED_BY="[Empty name]">
<P>We searched the Menstrual Disorders and Subfertility Group (MDSG) Specialised Register of controlled trials (<LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>) (May 2014) without language restriction and in consultation with the MDSG Trials Search Co-ordinator.</P>
<P>We conducted searches in the following electronic databases:</P>
<P>1. CENTRAL (<LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK>) (April 2014);<BR/>2. MEDLINE (<LINK REF="APP-03" TYPE="APPENDIX">Appendix 3</LINK>) (May 2014);<BR/>3. EMBASE (<LINK REF="APP-04" TYPE="APPENDIX">Appendix 4</LINK>) (May 2014);<BR/>4. PsycINFO (<LINK REF="APP-05" TYPE="APPENDIX">Appendix 5</LINK>) (May 2014);</P>
<P>5.CINAHL (<LINK REF="APP-06" TYPE="APPENDIX">Appendix 6</LINK>) (May 2014).</P>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2014-07-18 17:04:26 +1200" MODIFIED_BY="Helen E Nagels">
<P>Two review authors (AW, AK) searched online research databases without language or date restrictions (May 2014) including Clinicaltrials.gov, PubMed, LILACS/VHL, OpenGrey, ISI Web of Knowledge, World Health Organization (WHO) Clinical Trial Registries Platform and the Database of Abstracts of Reviews of Effects (DARE) in <I>The Cochrane Library</I>. We handsearched online relevant international and national peer-reviewed journals for relevant studies. These included:</P>
<UL>
<UL>
<OL>
<LI>Human Reproduction;</LI>
<LI>Human Reproduction Update;</LI>
<LI>Molecular Human Reproduction (MHR);</LI>
<LI>Fertility and Sterility;</LI>
<LI>American Journal of Obstetrics and Gynecology;</LI>
<LI>Best Practice &amp; Research. Clinical Obstetrics &amp; Gynaecology;</LI>
<LI>Current Obstetrics and Gynaecology;</LI>
<LI>European Journal of Obstetrics, Gynecology, and Reproductive Biology;</LI>
<LI>European Journal of Obstetrics and Gynecology;</LI>
<LI>Infertility and Reproductive Medicine Clinics of North America;</LI>
<LI>International Journal of Gynaecology and Obstetrics;</LI>
<LI>Journal of Reproductive Immunology;</LI>
<LI>Middle East Fertility Society Journal;</LI>
<LI>Obstetrics and Gynecology Clinics of North America;</LI>
<LI>Placenta;</LI>
<LI>Obstetrics, Gynaecology and Reproductive Medicine;</LI>
<LI>Reproductive BioMedicine Online;</LI>
<LI>Reproductive Health Matters;</LI>
<LI>Sexual &amp; Reproductive Healthcare;</LI>
<LI>Women's Health Issues;</LI>
<LI>Women's Health Medicine;</LI>
<LI>The Australian &amp; New Zealand Journal of Obstetrics &amp; Gynaecology;</LI>
<LI>Reproduction, Fertility, and Development;</LI>
<LI>American Journal Reproductive Immunology and Microbiology;</LI>
<LI>Biology of Reproduction;</LI>
<LI>Reproduction;</LI>
<LI>International Journal of Andrology.</LI>
</OL>
</UL>
</UL>
<P>In addition, we searched and checked reference lists of the included studies, and contacted authors for clarification of study methodology. We translated one article that was in French (<LINK REF="STD-Rongieres-2006" TYPE="STUDY">Rongieres 2006</LINK>) and one in Spanish (<LINK REF="STD-Aguirre-2010" TYPE="STUDY">Aguirre 2010</LINK>).</P>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2014-07-18 17:09:45 +1200" MODIFIED_BY="Helen E Nagels">
<STUDY_SELECTION MODIFIED="2014-07-05 21:09:23 +1200" MODIFIED_BY="[Empty name]">
<P>Three review authors (IK, AW, AK) independently examined the electronic search results for reports of possibly relevant trials. These reports were retrieved in full. Three review authors independently applied the selection criteria to the trial reports and resolved disagreements by discussion with the other review author (SB). AK and IK contacted authors for further clarification of study eligibility and methods.</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2014-07-05 21:09:57 +1200" MODIFIED_BY="[Empty name]">
<P>Data collection and analysis were conducted in accordance with the <I>Cochrane Handbook for Systematic Reviews of Interventions</I> (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>). Three review authors (IK, AW, AK) independently extracted the data and information using a data extraction form designed by the MDSG and pilot-tested by the authors. The review authors were not blinded to the authors or publication journal when doing this. Results were compared and any differences resolved by discussion. Where there was insufficient information in the published report, AK and IK contacted the authors to request further information and clarification.</P>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2014-07-05 21:10:58 +1200" MODIFIED_BY="[Empty name]">
<P>Three authors (IK, AK, AW) independently assessed each trial for risk of bias according to the <I>Cochrane Handbook for Systematic Reviews of Interventions</I> (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>). We assessed random sequence generation, allocation concealment, blinding, completeness of outcome data (including use of intention-to-treat (ITT) analysis) and selective outcome reporting for each trial. Other potential sources of bias were also assessed. Each trial was categorised as at low, unclear or high risk of bias for each domain based on the standards described in the <I>Cochrane Handbook for Systematic Reviews of Interventions</I> (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>). Where the method was not clearly reported, AK and IK contacted the authors for clarification.</P>
</QUALITY_ASSESSMENT>
<EFFECT_MEASURES MODIFIED="2014-07-05 21:11:34 +1200" MODIFIED_BY="[Empty name]">
<P>For dichotomous data we used the number of events in the control and intervention groups of each study to calculate Mantel-Haenszel odds ratios (ORs). For continuous data we calculated the mean difference (MD) between treatment groups. We presented 95% confidence intervals (CIs) for all outcomes.</P>
</EFFECT_MEASURES>
<UNIT_OF_ANALYSIS MODIFIED="2014-07-05 21:13:10 +1200" MODIFIED_BY="[Empty name]">
<P>The primary analyses were per woman randomised. For reported data that did not allow valid analysis (for example 'per cycle' rather than 'per woman', where the same women may contribute more than one cycle) and when contact with authors yielded no additional data or when contacts were unsuccessful, we excluded the outcomes<B> </B>from the analyses.</P>
</UNIT_OF_ANALYSIS>
<MISSING_DATA MODIFIED="2014-07-05 21:14:58 +1200" MODIFIED_BY="[Empty name]">
<P>We analysed the outcomes data of women as they were randomised by intention to treat (ITT). Trial authors were contacted for any missing data. Where no additional information was forthcoming and when we were not able to impute any missing values from available data, we excluded these outcomes<B> </B>from the analyses.</P>
</MISSING_DATA>
<HETEROGENEITY_ASSESSMENT MODIFIED="2014-07-05 21:15:09 +1200" MODIFIED_BY="[Empty name]">
<P>We considered whether the clinical and methodological characteristics of the included studies were sufficiently similar for meta-analysis to provide a clinically meaningful summary. For each meta-analysis, we assessed statistical heterogeneity using the I² and Chi² statistics. Substantial heterogeneity was determined to be present if I² was greater than 50%, or if P &lt; 0.05 in the Chi² test for heterogeneity (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>).</P>
</HETEROGENEITY_ASSESSMENT>
<BIAS_ASSESSMENT MODIFIED="2014-07-05 21:15:58 +1200" MODIFIED_BY="[Empty name]">
<P>We planned that a funnel plot would be constructed if 10 or more studies presented data on the same outcome.</P>
</BIAS_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2014-07-05 21:16:54 +1200" MODIFIED_BY="[Empty name]">
<P>Where appropriate, we combined dichotomous data for meta-analysis using the Mantel-Haenszel method to estimate pooled ORs with 95% CIs using a fixed-effect model. For continuous data, we computed weighted MD with 95% CI also using a fixed-effect model in the meta-analysis.</P>
</DATA_SYNTHESIS>
<SUBGROUP_ANALYSIS MODIFIED="2014-07-18 17:09:45 +1200" MODIFIED_BY="Helen E Nagels">
<P>We planned to conduct subgroup analysis to investigate heterogeneity, identified using the Chi² test (with P &lt; 0.05 as evidence of significant heterogeneity) and the I² statistic (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>), stratified by risk of bias in study design, where participants or assessors, or both, were blinded versus non-blinded, as well as by clinical characteristics of study populations such as OHSS risks categories and first IVF versus previously failed IVF attempts. We would have conducted these analyses had there been sufficient data available. </P>
</SUBGROUP_ANALYSIS>
<SENSITIVITY_ANALYSIS MODIFIED="2014-07-05 21:22:48 +1200" MODIFIED_BY="[Empty name]">
<P>As no included study reported our primary outcome of live birth rates per woman, we did not perform the planned sensitivity analysis to assess whether the findings were robust or whether the conclusions would have differed if eligibility was restricted to studies without a high risk of bias.</P>
<SUBSECTION>
<HEADING LEVEL="3">Summary of findings table</HEADING>
<P>We prepared a summary of findings table using GRADEpro software. This table evaluated the overall quality of the body of evidence for the primary review outcomes using GRADE criteria (study limitations (that is risk of bias), consistency of effect, imprecision, indirectness and publication bias). Judgements about evidence quality (high, moderate or low) were justified, documented, and incorporated into reporting of results for each outcome. See <LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>.</P>
</SUBSECTION>
</SENSITIVITY_ANALYSIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2014-08-06 17:19:26 +1200" MODIFIED_BY="Helen E Nagels">
<STUDY_DESCRIPTION MODIFIED="2014-08-01 13:41:52 +1200" MODIFIED_BY="Helen E Nagels">
<P>See <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>; <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK>.</P>
<SEARCH_RESULTS MODIFIED="2014-07-05 21:26:21 +1200" MODIFIED_BY="[Empty name]">
<P>In the original review, our search strategy identified 1119 potentially eligible reports of which two (<LINK REF="STD-Golan-1994" TYPE="STUDY">Golan 1994</LINK>; <LINK REF="STD-Lass-2003" TYPE="STUDY">Lass 2003</LINK>) met our inclusion criteria. They involved 411 women who underwent COH monitoring. One study (Murad 1998) was excluded as it was not a randomised controlled trial (RCT).<BR/>
<BR/>In the 2014 review update, an additional four studies (<LINK REF="STD-Aguirre-2010" TYPE="STUDY">Aguirre 2010</LINK>; <LINK REF="STD-Rongieres-2006" TYPE="STUDY">Rongieres 2006</LINK>; <LINK REF="STD-Strawn-2007" TYPE="STUDY">Strawn 2007</LINK>; <LINK REF="STD-Wiser-2012" TYPE="STUDY">Wiser 2012</LINK>) involving 370 women were identified. One of these included studies (<LINK REF="STD-Strawn-2007" TYPE="STUDY">Strawn 2007</LINK>) was reported as a conference abstract. Three studies were excluded: one was a quasi-randomised study (<LINK REF="STD-Schindler-2001" TYPE="STUDY">Schindler 2001</LINK>); one was not a randomised study (<LINK REF="STD-Kably-Ambe-1994" TYPE="STUDY">Kably Ambe 1994</LINK>); and the other was an RCT that compared combined monitoring with conventional two-dimensional (2D) and three-dimensional (3D) ultrasound instruments (<LINK REF="STD-Raine_x002d_Fenning-2010" TYPE="STUDY">Raine-Fenning 2010</LINK>). See <LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK> for details of the screening and selection process.</P>
</SEARCH_RESULTS>
<INCLUDED_STUDIES_DESCR MODIFIED="2014-08-01 13:41:52 +1200" MODIFIED_BY="Helen E Nagels">
<P>A total of six studies was included in this review (see <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>).</P>
<SUBSECTION>
<HEADING LEVEL="5">Study design and setting</HEADING>
<P>The six included studies were all RCTs published between 1994 and 2012 (<LINK REF="STD-Aguirre-2010" TYPE="STUDY">Aguirre 2010</LINK>; <LINK REF="STD-Golan-1994" TYPE="STUDY">Golan 1994</LINK>; <LINK REF="STD-Lass-2003" TYPE="STUDY">Lass 2003</LINK>; <LINK REF="STD-Rongieres-2006" TYPE="STUDY">Rongieres 2006</LINK>; <LINK REF="STD-Strawn-2007" TYPE="STUDY">Strawn 2007</LINK>; <LINK REF="STD-Wiser-2012" TYPE="STUDY">Wiser 2012</LINK>) and conducted in UK (N = 1), France (N = 1), Spain (N = 1), Israel (N = 2) and the US (N = 1). One was a multi-centre study involving four assisted conception units (<LINK REF="STD-Lass-2003" TYPE="STUDY">Lass 2003</LINK>). None of the trials specifically reported that the participants included egg donors. We did not identify any cross-over trials.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Participants</HEADING>
<P>The studies included 781 women (sample size ranged from 50 to 297), 394 in the control groups and 387 in the intervention groups, with an overall age range between 23 and 42 years. Two studies included only women admitted for the first IVF attempt (<LINK REF="STD-Golan-1994" TYPE="STUDY">Golan 1994</LINK>; <LINK REF="STD-Wiser-2012" TYPE="STUDY">Wiser 2012</LINK>) and two studies included women who had had less than three previous unsuccessful IVF cycles (<LINK REF="STD-Aguirre-2010" TYPE="STUDY">Aguirre 2010</LINK>; <LINK REF="STD-Lass-2003" TYPE="STUDY">Lass 2003</LINK>). Women for ICSI were excluded from one study (<LINK REF="STD-Lass-2003" TYPE="STUDY">Lass 2003</LINK>) and so were women with a previous history of serious OHSS (<LINK REF="STD-Rongieres-2006" TYPE="STUDY">Rongieres 2006</LINK>). Most participants were women with subfertility problems due to tubal factors, endometriosis, polycystic ovary syndrome (PCOS), male factors or unexplained infertility.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Interventions</HEADING>
<P>In this review, ovarian monitoring in the intervention group was conducted by TVUS only; and that of the control group by TVUS plus serum estradiol concentration. All six studies reported the use of TVUS to measure follicular growth. Details of COH protocols were not available for every study, and they differed in the use of agonist or antagonist gonadotrophin releasing hormone (GnRH), human menopausal gonadotrophin (hMG) or recombinant follicle stimulating hormone (rFSH). Three studies based the protocol used and dose according to individual response (<LINK REF="STD-Golan-1994" TYPE="STUDY">Golan 1994</LINK>) or as preferred or determined by the clinicians (<LINK REF="STD-Strawn-2007" TYPE="STUDY">Strawn 2007;</LINK> <LINK REF="STD-Wiser-2012" TYPE="STUDY">Wiser 2012</LINK>). In one study, all women had hormonal assays and ultrasound examinations but the results were only made known to the clinicians after oocyte retrieval (<LINK REF="STD-Golan-1994" TYPE="STUDY">Golan 1994</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Outcomes</HEADING>
<P>Primary outcomes: none of the six included studies reported the primary outcome of live birth rate. One study reported the ongoing pregnancy rate per cycle initiated (<LINK REF="STD-Strawn-2007" TYPE="STUDY">Strawn 2007</LINK>).</P>
<P>Secondary outcomes: four studies reported the outcome clinical pregnancy rate per woman (<LINK REF="STD-Aguirre-2010" TYPE="STUDY">Aguirre 2010</LINK>; <LINK REF="STD-Lass-2003" TYPE="STUDY">Lass 2003</LINK>; <LINK REF="STD-Rongieres-2006" TYPE="STUDY">Rongieres 2006</LINK>; <LINK REF="STD-Wiser-2012" TYPE="STUDY">Wiser 2012</LINK>). Two studies reported pregnancy rate per oocyte retrieval (<LINK REF="STD-Golan-1994" TYPE="STUDY">Golan 1994</LINK>; <LINK REF="STD-Strawn-2007" TYPE="STUDY">Strawn 2007</LINK>) and they were excluded from our analysis as no further details were provided when the authors were contacted. Five studies reported the number of oocytes retrieved per woman (<LINK REF="STD-Aguirre-2010" TYPE="STUDY">Aguirre 2010</LINK>; <LINK REF="STD-Golan-1994" TYPE="STUDY">Golan 1994</LINK>; <LINK REF="STD-Lass-2003" TYPE="STUDY">Lass 2003</LINK>; <LINK REF="STD-Strawn-2007" TYPE="STUDY">Strawn 2007</LINK>; <LINK REF="STD-Wiser-2012" TYPE="STUDY">Wiser 2012</LINK>). Three studies reported the number of cycle cancellations: due to OHSS (<LINK REF="STD-Strawn-2007" TYPE="STUDY">Strawn 2007</LINK>), insufficient treatment response (<LINK REF="STD-Wiser-2012" TYPE="STUDY">Wiser 2012</LINK>), and one study reported that cycle cancellation was similar in both arms but no data were presented (<LINK REF="STD-Rongieres-2006" TYPE="STUDY">Rongieres 2006</LINK>). One study presented the likely costs which might be saved by avoiding serum hormone determination (<LINK REF="STD-Golan-1994" TYPE="STUDY">Golan 1994</LINK>). All six studies reported the number of cases of OHSS.</P>
</SUBSECTION>
</INCLUDED_STUDIES_DESCR>
<EXCLUDED_STUDIES_DESCR MODIFIED="2014-07-05 21:41:27 +1200" MODIFIED_BY="[Empty name]">
<P>We excluded three studies. One was a quasi-randomised study (<LINK REF="STD-Schindler-2001" TYPE="STUDY">Schindler 2001</LINK>); one was not a randomised study (<LINK REF="STD-Kably-Ambe-1994" TYPE="STUDY">Kably Ambe 1994</LINK>); and one RCT (<LINK REF="STD-Raine_x002d_Fenning-2010" TYPE="STUDY">Raine-Fenning 2010</LINK>) compared combined monitoring with 3D ultrasound (US) versus 2D US (see <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK>).</P>
</EXCLUDED_STUDIES_DESCR>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2014-07-05 21:56:54 +1200" MODIFIED_BY="[Empty name]">
<P>See<I> </I>
<LINK TAG="STUDY_QUALITY" TYPE="SECTION">Risk of bias in included studies</LINK>; <LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK>; <LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK>.<I>
<BR/>
</I>
</P>
<ALLOCATION MODIFIED="2014-07-05 21:43:39 +1200" MODIFIED_BY="[Empty name]">
<P>Three studies were at low risk of selection bias related to random sequence generation as they used computer randomisation (<LINK REF="STD-Aguirre-2010" TYPE="STUDY">Aguirre 2010</LINK>; <LINK REF="STD-Lass-2003" TYPE="STUDY">Lass 2003</LINK>; <LINK REF="STD-Wiser-2012" TYPE="STUDY">Wiser 2012</LINK>). In one study women were randomised by 'drawing of lots' (<LINK REF="STD-Rongieres-2006" TYPE="STUDY">Rongieres 2006</LINK>) and the methods of randomisation were not described in two studies (<LINK REF="STD-Golan-1994" TYPE="STUDY">Golan 1994</LINK>; <LINK REF="STD-Strawn-2007" TYPE="STUDY">Strawn 2007</LINK>). These three studies were considered to be at an unclear risk of bias.</P>
<P>For allocation concealment, two studies used sealed envelopes (<LINK REF="STD-Wiser-2012" TYPE="STUDY">Wiser 2012</LINK>) with unique identification (ID) (<LINK REF="STD-Lass-2003" TYPE="STUDY">Lass 2003</LINK>) but did not give details whether the sealed envelopes were consecutively numbered and opaque, so they were rated as at unclear risk of bias. Four studies did not describe allocation concealment and were therefore at unclear risk of this bias (<LINK REF="STD-Aguirre-2010" TYPE="STUDY">Aguirre 2010</LINK>; <LINK REF="STD-Golan-1994" TYPE="STUDY">Golan 1994</LINK>; <LINK REF="STD-Rongieres-2006" TYPE="STUDY">Rongieres 2006</LINK>; <LINK REF="STD-Strawn-2007" TYPE="STUDY">Strawn 2007</LINK>). The authors were contacted but they were either not able to provide these methodological details or did not respond to our enquiry.</P>
</ALLOCATION>
<BLINDING MODIFIED="2014-07-05 21:44:50 +1200" MODIFIED_BY="[Empty name]">
<P>For the women participating in the studies, we did not consider that blinding was likely to influence the risk of performance bias for the IVF outcomes assessed. However, there was potential for performance and detection bias in the outcomes of fertilisation and subsequent clinical pregnancy when the operators were not blinded to the allocation. One study reported that patients were blinded for the allocation (<LINK REF="STD-Lass-2003" TYPE="STUDY">Lass 2003</LINK>) but did not describe the method. The other three studies did not report methods of patient blinding (<LINK REF="STD-Aguirre-2010" TYPE="STUDY">Aguirre 2010</LINK>; <LINK REF="STD-Golan-1994" TYPE="STUDY">Golan 1994</LINK>; <LINK REF="STD-Wiser-2012" TYPE="STUDY">Wiser 2012</LINK>).</P>
<P>In one study, women in the intervention and control groups received combined monitoring and results of estradiol levels were only made known to the clinicians after oocyte retrieval (<LINK REF="STD-Golan-1994" TYPE="STUDY">Golan 1994</LINK>).</P>
</BLINDING>
<EXCLUSIONS MODIFIED="2014-07-05 21:48:31 +1200" MODIFIED_BY="[Empty name]">
<P>Analysis of outcomes based on the ITT principle was conducted in one study (<LINK REF="STD-Golan-1994" TYPE="STUDY">Golan 1994</LINK>) where data were analysed as participants were randomised. Nine women had their treatment discontinued due to risk of OHSS: five from the TVUS group and three from the combined group (<LINK REF="STD-Lass-2003" TYPE="STUDY">Lass 2003</LINK>). Four women were excluded from the study due to non-adherence to the protocol (<LINK REF="STD-Aguirre-2010" TYPE="STUDY">Aguirre 2010</LINK>), and one women in the TVUS group was excluded due to insufficient response to treatment (<LINK REF="STD-Wiser-2012" TYPE="STUDY">Wiser 2012</LINK>). There was no report of attrition in one study (<LINK REF="STD-Rongieres-2006" TYPE="STUDY">Rongieres 2006</LINK>).</P>
<P>For the reporting of number of oocytes retrieved per woman, it was not clear from the included studies that the means for the number of oocytes were reported correctly, that is including zero counts for those women with cancelled cycles, as none of the included studies provided this information.</P>
</EXCLUSIONS>
<SELECTIVE_REPORTING MODIFIED="2014-07-05 21:51:08 +1200" MODIFIED_BY="[Empty name]">
<P>All six studies reported outcomes pre-specified in the methods section. One study reported comparable cycle cancellation rates and mean numbers of oocytes retrieved between the two arms but no data were presented (<LINK REF="STD-Rongieres-2006" TYPE="STUDY">Rongieres 2006</LINK>). Some outcomes were not of interest in this review, such as fertilisation rate, implantation rate, miscarriage rate, ectopic pregnancy rate, number of embryos transferred, duration of hMG treatment, number of hMG ampoules used and endometrial thickness, and these data were neither extracted nor analysed.</P>
</SELECTIVE_REPORTING>
<OTHER_BIAS_SOURCES MODIFIED="2014-07-05 21:56:54 +1200" MODIFIED_BY="[Empty name]">
<P>Use of a prospective power calculation was not reported in five studies (<LINK REF="STD-Aguirre-2010" TYPE="STUDY">Aguirre 2010</LINK>; <LINK REF="STD-Golan-1994" TYPE="STUDY">Golan 1994</LINK>; <LINK REF="STD-Rongieres-2006" TYPE="STUDY">Rongieres 2006</LINK>; <LINK REF="STD-Strawn-2007" TYPE="STUDY">Strawn 2007</LINK>; <LINK REF="STD-Wiser-2012" TYPE="STUDY">Wiser 2012</LINK>).</P>
<P>Defintions of clinical pregnancy were reported in three studies (<LINK REF="STD-Lass-2003" TYPE="STUDY">Lass 2003</LINK>; <LINK REF="STD-Rongieres-2006" TYPE="STUDY">Rongieres 2006</LINK>; <LINK REF="STD-Wiser-2012" TYPE="STUDY">Wiser 2012</LINK>) but none of the six studies provided a definition of OHSS or clarified whether the number of oocytes retrieved per woman was calculated to include zero count.</P>
<P>Another potential source of bias, imbalance in baseline characteristics, was deemed at low risk in four included studies (<LINK REF="STD-Aguirre-2010" TYPE="STUDY">Aguirre 2010</LINK>; <LINK REF="STD-Golan-1994" TYPE="STUDY">Golan 1994</LINK>; <LINK REF="STD-Lass-2003" TYPE="STUDY">Lass 2003</LINK>; <LINK REF="STD-Wiser-2012" TYPE="STUDY">Wiser 2012</LINK>) which reported similar baseline characteristics in relation to age, body mass index (BMI) and causes of infertility between the intervention and the control groups. Any baseline imbalance could be considered as a possible indicator of allocation bias. Two studies provided demographic details which were comparable between the two arms but there was no information on the causes of infertility (<LINK REF="STD-Rongieres-2006" TYPE="STUDY">Rongieres 2006</LINK>; <LINK REF="STD-Strawn-2007" TYPE="STUDY">Strawn 2007</LINK>).</P>
<P>Ovarian stimulation protocols differed between the two arms in three studies: according to the individual&#8217;s response (<LINK REF="STD-Golan-1994" TYPE="STUDY">Golan 1994</LINK>) and the physician&#8217;s preference (<LINK REF="STD-Strawn-2007" TYPE="STUDY">Strawn 2007</LINK>; <LINK REF="STD-Wiser-2012" TYPE="STUDY">Wiser 2012</LINK>).</P>
</OTHER_BIAS_SOURCES>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2014-08-06 17:19:26 +1200" MODIFIED_BY="Helen E Nagels">
<P>See <LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>.</P>
<SUBSECTION>
<HEADING LEVEL="3">Transvaginal ultrasound (TVUS) only versus TVUS plus serum estradiol concentrations</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">Primary outcome</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">Live birth rate</HEADING>
<UL>
<LI>None of the six included studies reported our primary outcome of live birth rate.</LI>
</UL>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Secondary outcomes</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">1. Pregnancy rate</HEADING>
<P>There was no evidence of a difference between ovarian monitoring with TVUS only and ovarian monitoring with TVUS plus estradiol measurement on the clinical pregnancy rate per woman. This outcome was reported in four studies (19/35 versus 14/35, 46/148 versus 49/149, 26/88 versus 30/97, and 19/34 versus 12/31, respectively; OR 1.10; 95% CI 0.79 to 1.54; N = 617; I² = 5%; low quality evidence) (<LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>, <LINK REF="FIG-04" TYPE="FIGURE">Figure 4</LINK>) (<LINK REF="STD-Aguirre-2010" TYPE="STUDY">Aguirre 2010</LINK>; <LINK REF="STD-Lass-2003" TYPE="STUDY">Lass 2003</LINK>; <LINK REF="STD-Rongieres-2006" TYPE="STUDY">Rongieres 2006</LINK>; <LINK REF="STD-Wiser-2012" TYPE="STUDY">Wiser 2012</LINK>). This suggested that compared with women with a 34% chance of clinical pregnancy using monitoring with TVUS plus serum estradiol, the clinical pregnancy rate in women using TVUS only was between 29% and 44%. Two studies measured the pregnancy rate per oocyte retrieval only and so were excluded from the analysis (<LINK REF="STD-Golan-1994" TYPE="STUDY">Golan 1994</LINK>; <LINK REF="STD-Strawn-2007" TYPE="STUDY">Strawn 2007</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2. Number of oocytes recovered per woman</HEADING>
<P>There was no evidence of a difference in the mean number of oocytes retrieved between the two arms in the five studies (MD 9.9 (SD 3.1) versus 10.9 (SD 4.2), 13.4 (SD 7.5) versus 11.7 (SD 8.4), 11.7 (SD 5.9) versus 11.4 (SD 6.1), 11 (SD 7.0) versus 9 (SD 4.0), and 11.7 (SD 8.0) versus 10.0 (SD 5.5), respectively; MD 0.32; 95% CI -0.60 to 1.24; N = 596; I² = 17%; low quality evidence) (<LINK REF="CMP-001.02" TYPE="ANALYSIS">Analysis 1.2</LINK>, <LINK REF="FIG-05" TYPE="FIGURE">Figure 5</LINK>) (<LINK REF="STD-Aguirre-2010" TYPE="STUDY">Aguirre 2010</LINK>; <LINK REF="STD-Golan-1994" TYPE="STUDY">Golan 1994</LINK>; <LINK REF="STD-Lass-2003" TYPE="STUDY">Lass 2003</LINK>; <LINK REF="STD-Strawn-2007" TYPE="STUDY">Strawn 2007</LINK>; <LINK REF="STD-Wiser-2012" TYPE="STUDY">Wiser 2012</LINK>).</P>
<P>One study reported a non-significant difference in the number of oocytes retrieved but no data were presented (<LINK REF="STD-Rongieres-2006" TYPE="STUDY">Rongieres 2006</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">3. Adverse outcomes</HEADING>
<SUBSECTION>
<HEADING LEVEL="6">3.1 Rate of ovarian hyperstimulation syndrome (OHSS), including severe OHSS</HEADING>
<P>No incidence of OHSS was reported in two studies (<LINK REF="STD-Aguirre-2010" TYPE="STUDY">Aguirre 2010</LINK>; <LINK REF="STD-Wiser-2012" TYPE="STUDY">Wiser 2012</LINK>). Combining the results of six studies, we found no difference in the total cases of OHSS between the two arms (0/35 versus 0/35, 0/34 versus 0/31, 1/25 versus 1/25, 4/57 versus 3/57, 7/148 versus 5/149, and 2/88 versus 5/97, respectively; OR 1.03; 95% CI 0.48 to 2.20; six studies; N = 781; I² = 0%; low quality evidence) (<LINK REF="CMP-001.03" TYPE="ANALYSIS">Analysis 1.3</LINK>, <LINK REF="FIG-06" TYPE="FIGURE">Figure 6</LINK>) (<LINK REF="STD-Aguirre-2010" TYPE="STUDY">Aguirre 2010</LINK>; <LINK REF="STD-Golan-1994" TYPE="STUDY">Golan 1994</LINK>; <LINK REF="STD-Lass-2003" TYPE="STUDY">Lass 2003</LINK>; <LINK REF="STD-Rongieres-2006" TYPE="STUDY">Rongieres 2006</LINK>; <LINK REF="STD-Strawn-2007" TYPE="STUDY">Strawn 2007</LINK>; <LINK REF="STD-Wiser-2012" TYPE="STUDY">Wiser 2012</LINK>), suggesting that compared with women with a 4% chance of OHSS using monitoring with TVUS plus serum estradiol, the OHSS rate in women monitored by TVUS only was between 2% and 8%.</P>
<P>Of the 28 cases of OHSS reported in all the six studies there were four cases of severe OHSS, which showed no difference between the two arms (1/57 versus 1/57 and 2/148 versus 0/149, respectively) (<LINK REF="STD-Golan-1994" TYPE="STUDY">Golan 1994</LINK>; <LINK REF="STD-Lass-2003" TYPE="STUDY">Lass 2003</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">3.2 Number of cancelled cycles</HEADING>
<P>Three studies reported this outcome. The cycle cancellation rate was similar in the two arms of two studies (0/34 versus 1/31, 1/25 versus 1/25; OR 0.57; 95% CI 0.07 to 4.39; N = 115; I² = 0%; low quality evidence) (<LINK REF="CMP-001.04" TYPE="ANALYSIS">Analysis 1.4</LINK>, <LINK REF="FIG-07" TYPE="FIGURE">Figure 7</LINK>) (<LINK REF="STD-Strawn-2007" TYPE="STUDY">Strawn 2007</LINK>; <LINK REF="STD-Wiser-2012" TYPE="STUDY">Wiser 2012</LINK>). The third study reported comparable cancellation rates between the two arms but no data were presented (<LINK REF="STD-Rongieres-2006" TYPE="STUDY">Rongieres 2006</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">4. Costs of monitoring with TVUS versus monitoring with TVUS plus serum estradiol concentration</HEADING>
<P>None of the six studies performed an economic analysis on the cost-effectiveness of the two different types of ovarian monitoring. However, one study (<LINK REF="STD-Golan-1994" TYPE="STUDY">Golan 1994</LINK>) suggested that US monitoring could be highly cost-effective and avoiding serum hormone determination might save over USD 150 (1994 prices) in each cycle and compensate for the cost of the GnRH analogue. No further details were available from the studies or the authors.</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2014-08-01 13:39:46 +1200" MODIFIED_BY="Helen E Nagels">
<SUMMARY_OF_RESULTS MODIFIED="2014-07-05 22:15:35 +1200" MODIFIED_BY="[Empty name]">
<P>There were no data on live births. With respect to pregnancy outcomes, in pooling the data of these six trials involving 781 women we found no evidence that cycle monitoring by TVUS alone was any less effective or efficacious than combined monitoring by TVUS plus estradiol assay. However, this interpretation was limited by the imprecision of the findings and the overall low quality of the included studies.</P>
</SUMMARY_OF_RESULTS>
<APPLICABILITY_OF_FINDINGS MODIFIED="2014-08-01 13:39:46 +1200" MODIFIED_BY="Helen E Nagels">
<P>Although the pooled results of these six studies suggest that TVUS alone may potentially be a satisfactory monitoring tool for women undergoing COH for IVF or ICSI, the overall completeness and applicability of the evidence is limited.</P>
<P>None of the studies reported our primary outcome of live births and all of the studies were of low methodological quality. One weakness was the variability of the inclusion criteria for participants. The studies included women undergoing their first IVF attempts (<LINK REF="STD-Golan-1994" TYPE="STUDY">Golan 1994</LINK>; <LINK REF="STD-Wiser-2012" TYPE="STUDY">Wiser 2012</LINK>) as well as women who had already received three previous IVF attempts (<LINK REF="STD-Aguirre-2010" TYPE="STUDY">Aguirre 2010</LINK>; <LINK REF="STD-Lass-2003" TYPE="STUDY">Lass 2003</LINK>). Women for both IVF and ICSI were included in one study (<LINK REF="STD-Rongieres-2006" TYPE="STUDY">Rongieres 2006</LINK>) and women for ICSI were excluded in one study (<LINK REF="STD-Lass-2003" TYPE="STUDY">Lass 2003</LINK>), as were women with previous serious OHSS (<LINK REF="STD-Rongieres-2006" TYPE="STUDY">Rongieres 2006</LINK>). Women undergoing ICSI (that is those with partners with male factor problems) may be younger than those receiving IVF. These different patient selection criteria may have led to bias in the results due to different responses to treatment. Excluding those with previous OHSS may lead to a spuriously lower proportion of women with this condition in a subsequent cycle. Women were enrolled for a single treatment cycle (<LINK REF="STD-Lass-2003" TYPE="STUDY">Lass 2003</LINK>), for more than one cycle (<LINK REF="STD-Aguirre-2010" TYPE="STUDY">Aguirre 2010</LINK>; <LINK REF="STD-Rongieres-2006" TYPE="STUDY">Rongieres 2006</LINK>), and three studies did not report the number of cycles (<LINK REF="STD-Golan-1994" TYPE="STUDY">Golan 1994</LINK>; <LINK REF="STD-Strawn-2007" TYPE="STUDY">Strawn 2007</LINK>; <LINK REF="STD-Wiser-2012" TYPE="STUDY">Wiser 2012</LINK>). The different inclusion criteria for women participating in the studies included in this review limit its generalisability.</P>
<P>Likewise, the criteria for stimulation protocols varied between the studies and it is not clear how this difference would influence the outcomes. In three studies all women were treated with a standardised protocol (<LINK REF="STD-Aguirre-2010" TYPE="STUDY">Aguirre 2010</LINK>; <LINK REF="STD-Golan-1994" TYPE="STUDY">Golan 1994</LINK>; <LINK REF="STD-Lass-2003" TYPE="STUDY">Lass 2003</LINK>) and in two trials differing protocols were offered depending on clinical assessment and physician preference (<LINK REF="STD-Strawn-2007" TYPE="STUDY">Strawn 2007</LINK>; <LINK REF="STD-Wiser-2012" TYPE="STUDY">Wiser 2012</LINK>). One study described a standardised protocol with all women receiving GnRH analogues initially and with 35% to 36% of the women receiving further GnRH antagonists depending on predefined criteria of estradiol level or presence of one follicle &#8805; 13 mm (<LINK REF="STD-Rongieres-2006" TYPE="STUDY">Rongieres 2006</LINK>). Furthermore, the timing of TVUS in cycles varied between studies though the significance of this is uncertain and likely reflects the individual local protocols.</P>
<P>There was a lack of definitions for the outcomes assessed. For the three studies which presented the definitions of clinical pregnancy (<LINK REF="STD-Lass-2003" TYPE="STUDY">Lass 2003</LINK>; <LINK REF="STD-Rongieres-2006" TYPE="STUDY">Rongieres 2006</LINK>; <LINK REF="STD-Wiser-2012" TYPE="STUDY">Wiser 2012</LINK>) they differed, ranging from 'fetal sac (with or without fetal heart activity) visualised by US on day 28 to 42 after hCG' (<LINK REF="STD-Lass-2003" TYPE="STUDY">Lass 2003</LINK>) to 'as confirmed by a fetal heartbeat determined by TVUS; approximately 32 days after embryo transfer' (<LINK REF="STD-Wiser-2012" TYPE="STUDY">Wiser 2012</LINK>) and 'presence of an intra-uterine gestational sac at US' (<LINK REF="STD-Rongieres-2006" TYPE="STUDY">Rongieres 2006</LINK>). The definition of OHSS was not presented in any of the studies and it was uncertain if the reported cases of 'severe' OHSS in two studies (<LINK REF="STD-Golan-1994" TYPE="STUDY">Golan 1994</LINK>; <LINK REF="STD-Lass-2003" TYPE="STUDY">Lass 2003</LINK>) were similar in nature. This lack of uniformity and consistency in outcomes definitions is an important shortcoming as there is potential for the assessed outcomes to be different, thus affecting the generalisability and applicability of the evidence.</P>
<P>Some studies either did not report or were unable to provide information to allow computation of outcomes 'per woman' when 'per cycle' data only were reported. This resulted in two studies being excluded from the analysis for the outcome on pregnancy rate (<LINK REF="STD-Golan-1994" TYPE="STUDY">Golan 1994</LINK>; <LINK REF="STD-Strawn-2007" TYPE="STUDY">Strawn 2007</LINK>), further limiting the evidence base, its generalisability and applicability. Our attempts to contact the authors were unsuccessful and we received no response.</P>
<P>Cycle monitoring with both TVUS and estradiol measurement is likely to involve higher costs (to cover technicians and laboratory costs, outpatient attendance) when compared with TVUS alone. Hormonal assays involve repeated venepuncture, which may cause stress and anxiety to women. However, it is unclear if women would be more satisfied with combined monitoring and because of a placebo effect with the perception that they are being monitored more closely. In future research it would be useful to know which monitoring protocol women were more satisfied with.</P>
</APPLICABILITY_OF_FINDINGS>
<QUALITY_OF_EVIDENCE MODIFIED="2014-08-01 13:37:28 +1200" MODIFIED_BY="Helen E Nagels">
<P>Using GRADE methods, the overall quality of the evidence was rated as low for all comparisons (<LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>). The main reasons for downgrading the quality of the evidence were risk of bias and imprecision. The methodological quality of the included studies was poor. This was largely due to some studies failing to describe their methods in adequate detail, such as methods of randomisation and allocation concealment and patient characteristics, resulting in the small quantity of relevant usable data that was available. In addition, five of the six studies did not conduct data analyses based on the ITT principle. Our efforts to contact study authors for further information were unsuccessful.<BR/>
</P>
<P>The addition of new trials in this update enables the aggregation of outcomes data, especially for pregnancy rate per woman. The methodological quality of the trials was variable (<LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK>, <LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK>). Population and treatment characteristics could influence the success of the IVF treatment. It is difficult to determine whether or not there was significant clinical heterogeneity as there was a lack of methodological details, particularly in the pilot study presented as a conference abstract (<LINK REF="STD-Strawn-2007" TYPE="STUDY">Strawn 2007</LINK>). Overall, the included studies appeared to investigate a shared research question with the same intervention and comparator. Five of the six included studies took place in assisted reproduction units (<LINK REF="STD-Aguirre-2010" TYPE="STUDY">Aguirre 2010</LINK>; <LINK REF="STD-Golan-1994" TYPE="STUDY">Golan 1994</LINK>; <LINK REF="STD-Lass-2003" TYPE="STUDY">Lass 2003</LINK>; <LINK REF="STD-Rongieres-2006" TYPE="STUDY">Rongieres 2006</LINK>; <LINK REF="STD-Wiser-2012" TYPE="STUDY">Wiser 2012</LINK>).</P>
<P>Blinding was variably reported in the studies. Women may feel either anxious or reassured if they receive combined monitoring and in this context an unblinded design would be potentially beneficial to measure certain outcomes. However, women's perception of anxiety or reassurance from venepuncture for estradiol measurement is unlikely to influence live birth and pregnancy rates. Assessor blinding would reduce performance and detection bias in oocyte retrieval and embryo transfer when they are not aware of the women's allocation status. In one study, women in the intervention and control groups received combined monitoring and results of the estradiol levels were made known to the clinicians after oocyte retrieval (<LINK REF="STD-Golan-1994" TYPE="STUDY">Golan 1994</LINK>). Studies whereby women are not blinded to their monitoring regime may be of clinical interest in the future.</P>
<P>There was a possibility that some of the randomised women may not have reached oocyte recovery stage due to cycles cancelled for inappropriate COH (either an under or over response). This is important in trials where ovarian response may be affected by the monitoring regimen. In one study (<LINK REF="STD-Lass-2003" TYPE="STUDY">Lass 2003</LINK>) nine women left the study before the hCG injection, six due to failure of human rFSH treatment, one because of risk of OHSS, one received saline instead of hCG, and one woman failed to follow the drug protocol. In this study a total of 42 women (14.1%) did not reach the embryo transfer stage, although the reasons for discontinuing treatment did not differ between the two groups.</P>
<P>For the reporting of number of oocytes retrieved per woman, it was not clear from the included studies that the means reported for oocytes correctly included zero counts for those with cancelled cycles. This would have the effect of both increasing the mean and reducing the standard deviation (SD), therefore exaggerating the statistical significance of the comparisons. Lack of this information from the studies and the authors increases the uncertainty of data reliability. In addition, the interpretation of US may potentially differ because it involves some degree of inter-observer variability, especially in units where successive scans may be performed by different personnel.</P>
<P>We contacted all authors for missing and additional information about their studies but received no response. One author responded that the data were no longer available due to the long time lapse from when the study was conducted, 20 years ago.</P>
</QUALITY_OF_EVIDENCE>
<POTENTIAL_BIASES MODIFIED="2014-05-19 17:07:59 +1200" MODIFIED_BY="[Empty name]">
<P>We did not exclude studies on the grounds of language and included one Spanish and one French study. One study was a conference abstract. Despite our efforts to contact authors, we were unable to obtain further information from them and some bias in the review process could have arisen due to the inclusion of trials with insufficient information on methods and outcome data and where authors did not respond to our enquiries.<BR/>
</P>
</POTENTIAL_BIASES>
<AGREEMENT MODIFIED="2014-07-05 22:53:43 +1200" MODIFIED_BY="[Empty name]">
<P>A recent systematic review of six studies reported that, compared to TVUS plus hormonal measurement, monitoring COH with TVUS only was unlikely to substantially change the chance of achieving clinical pregnancy outcomes in women undergoing IVF treatment (<LINK REF="REF-Martins-2013" TYPE="REFERENCE">Martins 2013</LINK>). They included five studies, all of which were included in this review except for one (<LINK REF="STD-Strawn-2007" TYPE="STUDY">Strawn 2007</LINK>).</P>
<P>One RCT that compared combined monitoring with traditional two-dimensional (2D) US versus automated three-dimensional (3D) US reported comparable outcomes for clinical pregnancy, number of oocytes retrieved and number of fertilised oocytes (<LINK REF="STD-Raine_x002d_Fenning-2010" TYPE="STUDY">Raine-Fenning 2010</LINK>). This suggests that traditional 2D US is no more or less efficient than 3D ultrasound for monitoring stimulated cycles in assisted reproduction.</P>
<P>A recent study to validate the saliva-based estradiol assay for intra- and inter-assay variability found that it was associated with improved patient satisfaction and reduced anxiety (<LINK REF="REF-Zimon-2013" TYPE="REFERENCE">Zimon 2013</LINK>), and this method may provide an equivalent but 'patient-friendly' alternative to serum-based assessment. However, in the absence of any effectiveness and cost-effectiveness data from RCTs comparing the effects of serum estradiol and saliva-based estradiol assays, the non-invasive saliva-based estradiol assay would still incur anxiety and costs. Serum estradiol may be perceived as a more reliable parameter, especially in women at risk of OHSS in whom decisions on cycle cancellation or elective freezing of oocytes or embryos may need to be taken. However, as the findings of this review show that current evidence is limited, high quality RCTs to assess monitoring methods would be welcome. A cycle monitoring protocol including both US and serum estradiol concentrations may need to be retained as precautionary good clinical practice and in a subset of women as a confirmatory test to identify those at high risk of OHSS, such as women with a history of OHSS or with polycystic ovaries, those exposed to ovulation induction, and younger women undergoing assisted reproduction techniques (<LINK REF="REF-Jenkins-2006" TYPE="REFERENCE">Jenkins 2006</LINK>).</P>
<P>No formal cost analysis was reported in these studies. The studies reviewed were not designed to test the cost-effectiveness of the two interventions. However, it was suggested that avoiding serum hormone determination might save over USD 150 (at early 1990 prices) in each cycle and this would compensate for the cost of the GnRHa (<LINK REF="STD-Golan-1994" TYPE="STUDY">Golan 1994</LINK>).</P>
</AGREEMENT>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2014-07-05 22:55:31 +1200" MODIFIED_BY="[Empty name]">
<IMPLICATIONS_PRACTICE MODIFIED="2014-07-05 22:53:14 +1200" MODIFIED_BY="[Empty name]">
<P>This review update found no evidence from randomised controlled trials to suggest that combined monitoring by TVUS and serum estradiol is more efficacious than monitoring by TVUS alone, with regard to clinical pregnancy rates and the incidence of OHSS. The number of oocytes retrieved appeared similar for both monitoring protocols. The data suggest that both of these monitoring methods are safe and reliable. However, these results should be interpreted with caution because the overall quality of the evidence was low. Results were compromised by imprecision and poor reporting of study methodology. A combined monitoring protocol including both TVUS and serum estradiol may need to be retained as precautionary good clinical practice and as a confirmatory test in a subset of women to identify those at high risk of OHSS.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2014-07-05 22:55:31 +1200" MODIFIED_BY="[Empty name]">
<P>To find a difference in an important but rare outcome such as OHSS, a large randomised controlled study requiring the recruitment of approximately 5000 women is needed for each randomised arm, and this would pose a great methodological challenge. Based on the quoted risk of OHSS following IVF in Europe of 1% (<LINK REF="REF-Ferraretti-2012" TYPE="REFERENCE">Ferraretti 2012</LINK>) and a hypothetical trial of an intervention for reduction of OHSS with a clinically meaningful effect size, meaning to halve this risk (from 1% to 0.5%) with 90% power and 95% confidence (alpha = 0.05), the trial would need 4675 women in each randomised arm. However, an economic evaluation of the costs involved in these two monitoring methods and assessing the views of the women undergoing cycle monitoring would be welcome.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2014-07-05 22:56:38 +1200" MODIFIED_BY="[Empty name]">
<P>We are grateful to Marian Showell for her help in updating the search strategy and carrying out the literature search; to Anne Lethaby for translating the Spanish paper and extracting data; and in particular to Helen Nagels and Jane Marjoribanks for their editorial assistance, help with GRADEpro, general co-ordination and assisting with teleconferences among authors. We also thank Helen Nagels for her help in translating the French paper and extracting the data.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST>
<P>None known</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2014-07-05 22:58:17 +1200" MODIFIED_BY="[Empty name]">
<P>IK took the lead in writing the draft of the protocol, developed the intended methods of the review, was involved in selecting trials for inclusion, performed independent data extraction and quality assessment of included trials, contacted authors for additional information and was responsible for statistical analyses, and writing the final review.</P>
<P>SB helped to develop the protocol and intended methods of the review, was consultant on clinical issues, made significant contributions to the interpretation of results and improvement of the final review.</P>
<P>AW and AK were involved in selecting trials for inclusion, contacting authors for additional information, performed independent data extraction and quality assessment of included trials. AW contributed to the statistical analyses and interpretation of results, provided clinical input and helped to write the final review.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF MODIFIED="2013-10-07 03:20:27 +1300" MODIFIED_BY="Irene OL Kwan">
<P>None</P>
</PRO_REV_DIFF>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2014-07-18 17:20:19 +1200" MODIFIED_BY="Helen E Nagels">
<STUDIES MODIFIED="2014-07-18 17:20:19 +1200" MODIFIED_BY="Helen E Nagels">
<INCLUDED_STUDIES MODIFIED="2014-07-18 17:20:19 +1200" MODIFIED_BY="Helen E Nagels">
<STUDY DATA_SOURCE="PUB" ID="STD-Aguirre-2010" MODIFIED="2013-08-08 03:54:16 +1200" MODIFIED_BY="Kwan I " NAME="Aguirre 2010" YEAR="2010">
<REFERENCE MODIFIED="2013-08-08 03:53:07 +1200" MODIFIED_BY="Kwan I " PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Aguirre SG, Hevia IG, García-Carpintero G, DelRosal Ma J</AU>
<TI>Measuring plasma estradiol levels in in vitro fertilization. Is it useful?</TI>
<SO>Revista Iberoamericana De Fertilidad y Reproduccion Humana</SO>
<YR>2010</YR>
<VL>27</VL>
<NO>1</NO>
<PG>43-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2013-08-08 03:54:16 +1200" MODIFIED_BY="Kwan I "/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Golan-1994" NAME="Golan 1994" YEAR="1994">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Golan A, Herman A, Soffer Y, Bukovsky I, Ron-El R</AU>
<TI>Ultrasonic control without hormone determination for ovulation induction in in-vitro fertilization/embryo transfer with gonadotrophin-releasing hormone analogue and human menopausal gonadotrophin</TI>
<SO>Human Reproduction</SO>
<YR>1994</YR>
<VL>9(9)</VL>
<PG>1631-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lass-2003" NAME="Lass 2003" YEAR="2003">
<REFERENCE NOTES="&lt;p&gt;Lass A, UK Timing of hCG Group. Monitoring of in vitro fertilization-embryo transfer cycles by ultrasound versus by ultrasound and hormonal levels: a prospective, multicenter, randomized study. Fertility Sterility 2003;80(1):80-5.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lass A, UK Timing of hCG Group</AU>
<TI>Monitoring of in vitro fertilization-embryo transfer cycles by ultrasound versus by ultrasound and hormonal levels: a prospective, multicenter, randomized study</TI>
<SO>Fertility and Sterility</SO>
<YR>2003</YR>
<VL>80(1)</VL>
<PG>80-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rongieres-2006" MODIFIED="2014-07-18 17:20:19 +1200" MODIFIED_BY="Helen E Nagels" NAME="Rongieres 2006" YEAR="2006">
<REFERENCE MODIFIED="2014-07-18 17:20:19 +1200" MODIFIED_BY="Helen E Nagels" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rongieres C</AU>
<TI>Monitoring ovarian stimulation: are hormonal assessments necessary?</TI>
<SO>Journal de Gynécologie, Obstétrique et Biologie de la Reproduction</SO>
<YR>2006</YR>
<VL>35</VL>
<PG>2S39-41</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2013-11-18 02:51:41 +1300" MODIFIED_BY="Irene OL Kwan"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Strawn-2007" MODIFIED="2014-07-05 23:12:05 +1200" MODIFIED_BY="[Empty name]" NAME="Strawn 2007" YEAR="2007">
<REFERENCE MODIFIED="2014-07-05 23:12:05 +1200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Strawn EY, Roesler M, Granlund A, Bohling S</AU>
<TI>In vitro fertilization can be successfully accomplished without routine estradiol monitoring: a randomized pilot study</TI>
<SO>Fertility and Sterility</SO>
<YR>2007</YR>
<VL>88 Suppl 1</VL>
<NO>P-114</NO>
<PG>S147</PG>
<EN>American Society for Reprodyuctive Medidine (ARSM) 63rd Annual Meeting, Washington DC, 10 October 2007</EN>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wiser-2012" MODIFIED="2014-07-05 23:12:31 +1200" MODIFIED_BY="[Empty name]" NAME="Wiser 2012" YEAR="2012">
<REFERENCE MODIFIED="2014-07-05 23:12:31 +1200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wiser A, Gonen O, Ghetler Y, Shavit T, Berkovitz A, Shulman A</AU>
<TI>Monitoring stimulated cycles during in vitro fertilization treatment with ultrasound only &#8211; preliminary results</TI>
<SO>Gynecological Endocrinology</SO>
<YR>2012</YR>
<VL>28</VL>
<NO>6</NO>
<PG>429&#8211;31</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2014-07-05 23:13:41 +1200" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Kably-Ambe-1994" MODIFIED="2013-11-10 02:18:27 +1300" MODIFIED_BY="Irene OL Kwan" NAME="Kably Ambe 1994" YEAR="1994">
<REFERENCE MODIFIED="2013-11-10 02:18:27 +1300" MODIFIED_BY="Irene OL Kwan" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kably Ambe A, Carranza Lira S, Serviere Zaragoza C, Espinoza de los Monteros A, Coria Soto I, Alvarado Duran A</AU>
<TI>The evaluation of the usefulness of ultrasound independent of estradiol as a prognostic criterion for ovular capture and maturity A comparative double-blind study</TI>
<SO>Ginecologia y Obstetricia de Mexico</SO>
<YR>1994</YR>
<VL>62</VL>
<PG>288-91</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Raine_x002d_Fenning-2010" MODIFIED="2013-11-02 08:40:11 +1300" MODIFIED_BY="Irene OL Kwan" NAME="Raine-Fenning 2010" YEAR="2010">
<REFERENCE MODIFIED="2013-11-02 08:40:11 +1300" MODIFIED_BY="Irene OL Kwan" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Raine-Fenning N, Deb S, Jayaprakasan K, Clewes J, Hopkisson J, Campbell B</AU>
<TI>Timing of oocyte maturation and egg collection during controlled ovarian stimulation: a randomized controlled trial evaluating manual and automated measurements of follicle diameter</TI>
<SO>Fertility and Sterility</SO>
<YR>2010</YR>
<VL>94</VL>
<NO>1</NO>
<PG>184-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Schindler-2001" MODIFIED="2014-07-05 23:13:41 +1200" MODIFIED_BY="[Empty name]" NAME="Schindler 2001" YEAR="2007">
<REFERENCE MODIFIED="2014-07-05 23:13:41 +1200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schindler L, Janny L, Canis M, Schubert B, Durakovic N</AU>
<TI>Oestradiol is useless in IVF monitoring: a prospective study</TI>
<SO>Human Reproduction</SO>
<YR>2001</YR>
<VL>16 Suppl 1</VL>
<NO>P-269</NO>
<PG>204</PG>
<EN>Abstracts of the 17th Annual Meeting of the ESHRE, lausanne, Switzerland</EN>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES/>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2014-07-05 23:23:11 +1200" MODIFIED_BY="[Empty name]">
<ADDITIONAL_REFERENCES MODIFIED="2014-07-05 23:23:11 +1200" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Abdalla-1989" NAME="Abdalla 1989" NOTES="&lt;p&gt;Abdalla HI, Baber RJ, Leonard T, Kirkland A, Mitchell A, Power M, Owen E, Studd JW. Timed oocyte collection in an assisted conception programme using GnRH analogue. Human Reproduction 1989;4(8):927-30.&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Abdalla HI, Baber RJ, Leonard T, Kirkland A, Mitchell A, Power M et al</AU>
<TI>Timed oocyte collection in an assisted conception programme using GnRH analogue</TI>
<SO>Human Reproduction</SO>
<YR>1989</YR>
<VL>4</VL>
<NO>8</NO>
<PG>927-30</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Asch-1991" NAME="Asch 1991" NOTES="&lt;p&gt;1.Asch RH, Li HP, Balmaceda JP, Weckstein LN, Stone SC. Severe ovarian hyperstimulation syndrome in assisted reproductive technology: definition of high risk groups. Human Reproduction. 1991;6(10):1395-9.&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Asch RH, Li HP, Balmaceda JP, Weckstein LN, Stone SC</AU>
<TI>Severe ovarian hyperstimulation syndrome in assisted reproductive technology: definition of high risk groups</TI>
<SO>Human Reproduction</SO>
<YR>1991</YR>
<VL>6</VL>
<NO>10</NO>
<PG>1395-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Borase-2012" MODIFIED="2014-07-05 23:16:45 +1200" MODIFIED_BY="[Empty name]" NAME="Borase 2012" TYPE="JOURNAL_ARTICLE">
<AU>Borase H, Mathur R</AU>
<TI>Ovarian hyperstimulation syndrome: clinical features, prevention and management</TI>
<SO>Obstetrics, Gynaecology and Reproductive Medicine</SO>
<YR>2012</YR>
<VL>22</VL>
<NO>7</NO>
<PG>186-90</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Confino-1996" NAME="Confino 1996" NOTES="&lt;p&gt;Confino E, Binor Z, Molo MW, Rawlins R, Balos R, Mullaney K, Radwanska E. Sonographically monitored ovarian stimulation for assisted reproduction: a prospective, blind study. J Reprod Med. 1996;41(1):7-10.&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Confino E, Binor Z, Molo MW, Rawlins R, Balos R, Mullaney K et al</AU>
<TI>Sonographically monitored ovarian stimulation for assisted reproduction: a prospective, blind study</TI>
<SO>Journal of Reproductive Medicine</SO>
<YR>1996</YR>
<VL>41(1)</VL>
<PG>7-10</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Delvigne-2002" MODIFIED="2014-07-05 23:17:10 +1200" MODIFIED_BY="[Empty name]" NAME="Delvigne 2002" TYPE="JOURNAL_ARTICLE">
<AU>Delvigne A, Rozenberg S</AU>
<TI>Epidemiology and prevention of ovarian hyperstimulation syndrome (OHSS): a review</TI>
<SO>Human Reproduction Update</SO>
<YR>2002</YR>
<VL>8</VL>
<NO>6</NO>
<PG>559-77</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ferraretti-2012" MODIFIED="2014-07-05 23:17:54 +1200" MODIFIED_BY="[Empty name]" NAME="Ferraretti 2012" TYPE="JOURNAL_ARTICLE">
<AU>Ferraretti AP, Goossens V, de Mouzon J, Bhattacharya S, Castilla JA, Korsak V et al</AU>
<TI>The European IVF-monitoring (EIM), and Consortium, for the European Society of Human Reproduction and Embryology (ESHRE)</TI>
<SO>Human Reproduction</SO>
<YR>2012</YR>
<VL>27</VL>
<NO>9</NO>
<PG>2571-84</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Haning-1982" NAME="Haning 1982" NOTES="&lt;p&gt;Haning RV Jr, Austin CW, Kuzma DL, Shapiro SS, Zweibel WJ. Ultrasound evaluation of estrogen monitoring for induction of ovulation with menotropins. Fertility Sterility 1982;37(5):627-32.&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Haning RV Jr, Austin CW, Kuzma DL, Shapiro SS, Zweibel WJ</AU>
<TI>Ultrasound evaluation of estrogen monitoring for induction of ovulation with menotropins</TI>
<SO>Fertility and Sterility</SO>
<YR>1982</YR>
<VL>37</VL>
<NO>5</NO>
<PG>627-32</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hardiman-1990" NAME="Hardiman 1990" NOTES="&lt;p&gt;Hardiman P, Thomas M, Osgood V, Vlassopoulou V, Ginsburg J. Are estrogen assays essential for monitoring gonadotropin stimulant therapy? Gynecol Endocrinol. 1990;4(4):261-9.&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Hardiman P, Thomas M, Osgood V, Vlassopoulou V, Ginsburg J</AU>
<TI>Are estrogen assays essential for monitoring gonadotropin stimulant therapy?</TI>
<SO>Gynecological Endocrinology</SO>
<YR>1990</YR>
<VL>4</VL>
<NO>4</NO>
<PG>261-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2011" MODIFIED="2014-04-02 16:53:22 +1300" MODIFIED_BY="Irene OL Kwan" NAME="Higgins 2011" TYPE="BOOK">
<AU>Higgins J PT, Green S, editors</AU>
<SO>Cochrane Handbook of Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]</SO>
<YR>2011. Available from www.cochrane-handbook.org</YR>
<PB>The Cochrane Collaboration</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Howard-1988" NAME="Howard 1988" NOTES="&lt;p&gt;Howard WF, Chihal HJ, Strain CA, Smith M. Programmed follicular stimulation reduces cycle cost and stress with no compromise in cycle quality: use of a modified programmed protocol. J In Vitro Fert Embryo Transf. 1988;5(6):343-6.&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Howard WF, Chihal HJ, Strain CA, Smith M</AU>
<TI>Programmed follicular stimulation reduces cycle cost and stress with no compromise in cycle quality: use of a modified programmed protocol</TI>
<SO>Journal of In Vitro Fertilisation and Embryo Transfer</SO>
<YR>1988</YR>
<VL>5</VL>
<NO>6</NO>
<PG>343-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Jenkins-2006" MODIFIED="2013-12-07 09:49:28 +1300" MODIFIED_BY="Irene OL Kwan" NAME="Jenkins 2006" TYPE="BOOK">
<AU>Jenkins JM, Drakeley AJ, Mathur RS</AU>
<SO>The management of ovarian hyperstimulation syndrome (RCOG Green-top Guideline No. 5)</SO>
<YR>2006</YR>
<PB>Royal College of Obstetricians and Gynaecologists</PB>
<CY>London</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kemeter-1989" MODIFIED="2014-07-05 23:19:02 +1200" MODIFIED_BY="[Empty name]" NAME="Kemeter 1989" NOTES="&lt;p&gt;Kemeter P, Feichtinger W. Experience with a new fixed-stimulation protocol without hormone determinations for programmed oocyte retrieval for in-vitro fertilization. Human Reproduction 1989;4(8 Suppl):53-8.&lt;/p&gt;" NOTES_MODIFIED="2014-07-05 23:19:02 +1200" NOTES_MODIFIED_BY="[Empty name]" TYPE="JOURNAL_ARTICLE">
<AU>Kemeter P, Feichtinger W</AU>
<TI>Experience with a new fixed-stimulation protocol without hormone determinations for programmed oocyte retrieval for in-vitro fertilization</TI>
<SO>Human Reproduction</SO>
<YR>1989</YR>
<VL>4</VL>
<NO>8 Suppl</NO>
<PG>53-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-MacDougall-1992" NAME="MacDougall 1992" TYPE="JOURNAL_ARTICLE">
<AU>MacDougall MJ, Tan SL, Jacobs HS</AU>
<TI>In-vitro fertilization and the ovarian hyperstimulation syndrome</TI>
<SO>Human Reproduction</SO>
<YR>1992</YR>
<VL>7</VL>
<NO>5</NO>
<PG>597-600</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Martins-2013" MODIFIED="2014-07-05 23:19:43 +1200" MODIFIED_BY="[Empty name]" NAME="Martins 2013" TYPE="JOURNAL_ARTICLE">
<AU>Martins WP, Vieira CV, Teixeira DM, Barbosa MA, Dassunção LA, Nastri CO</AU>
<TI>Ultrasound for monitoring controlled ovarian stimulation: a systematic review and meta-analysis of randomized controlled trials</TI>
<SO>Ultrasound Obstetrics and Gynecology</SO>
<YR>2014</YR>
<VL>43</VL>
<NO>1</NO>
<PG>25-33</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Murad-1998" NAME="Murad 1998" NOTES="&lt;p&gt;Murad NM. Ultrasound or ultrasound and hormonal determinations for in vitro fertilization monitoring. Int J Gynaecol Obstet. 1998;63(3):271-6.&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Murad NM</AU>
<TI>Ultrasound or ultrasound and hormonal determinations for in vitro fertilization monitoring</TI>
<SO>International Journal of Gynaecology and Obstetrics</SO>
<YR>1998</YR>
<VL>63</VL>
<NO>3</NO>
<PG>271-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Nygren-2002" NAME="Nygren 2002" TYPE="JOURNAL_ARTICLE">
<AU>Nygren KG, Andersen AN</AU>
<TI>Assisted reproductive technology in Europe, 1999. Results generated from European registers by ESHRE</TI>
<SO>Human Reproduction</SO>
<YR>2002</YR>
<VL>17</VL>
<NO>12</NO>
<PG>3260-74</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Rainhorn-1987" NAME="Rainhorn 1987" NOTES="&lt;p&gt;Rainhorn JD, Forman RG, Belaisch-Allart J, Hazout A, Fries N, Testart J, Frydman R. One year's experience with programmed oocyte retrieval for IVF. Human Reproduction 1987;2(6):491-4.&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Rainhorn JD, Forman RG, Belaisch-Allart J, Hazout A, Fries N, Testart J et al</AU>
<TI>One year's experience with programmed oocyte retrieval for IVF</TI>
<SO>Human Reproduction</SO>
<YR>1987</YR>
<VL>2</VL>
<NO>6</NO>
<PG>491-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Rizk-1992" NAME="Rizk 1992" TYPE="JOURNAL_ARTICLE">
<AU>Rizk B, Smitz J</AU>
<TI>Ovarian hyperstimulation syndrome after superovulation using GnRH agonists for IVF and related procedures</TI>
<SO>Human Reproduction</SO>
<YR>1992</YR>
<VL>7</VL>
<NO>3</NO>
<PG>320-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Roest-1995" NAME="Roest 1995" TYPE="JOURNAL_ARTICLE">
<AU>Roest J, Verhoeff A, van Heusden AM, Zeilmaker GH</AU>
<TI>Minimal monitoring of ovarian hyperstimulation: a useful simplification of the clinical phase of in vitro fertilization treatment</TI>
<SO>Fertility and Sterility</SO>
<YR>1995</YR>
<VL>64</VL>
<NO>3</NO>
<PG>552-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Roest-1996" NAME="Roest 1996" TYPE="JOURNAL_ARTICLE">
<AU>Roest J, Mous HV, Zeilmaker GH, Verhoeff A</AU>
<TI>The incidence of major clinical complications in a Dutch transport IVF programme</TI>
<SO>Human Reproduction Update</SO>
<YR>1996</YR>
<VL>2</VL>
<NO>4</NO>
<PG>345-53</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Schenker-1978" MODIFIED="2014-07-05 23:20:36 +1200" MODIFIED_BY="[Empty name]" NAME="Schenker 1978" TYPE="JOURNAL_ARTICLE">
<AU>Schenker JG, Weinstein D</AU>
<TI>Ovarian hyperstimulation syndrome: a current survey</TI>
<SO>Fertility and Sterility</SO>
<YR>1978</YR>
<VL>30</VL>
<NO>3</NO>
<PG>255-68</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Shoham-1991" NAME="Shoham 1991" NOTES="&lt;p&gt;Shoham Z, Di Carlo C, Patel A, Conway GS, Jacobs HS. Is it possible to run a successful ovulation induction program based solely on ultrasound monitoring? The importance of endometrial measurements. Fertility Sterility 1991;56(5):836-41.&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Shoham Z, Di Carlo C, Patel A, Conway GS, Jacobs HS</AU>
<TI>Is it possible to run a successful ovulation induction program based solely on ultrasound monitoring? The importance of endometrial measurements</TI>
<SO>Fertility and Sterility</SO>
<YR>1991</YR>
<VL>56</VL>
<NO>5</NO>
<PG>836-41</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Smitz-1990" NAME="Smitz 1990" TYPE="JOURNAL_ARTICLE">
<AU>Smitz J, Camus M, Devroey P, Erard P, Wisanto A, Van Steirteghem AC</AU>
<TI>Incidence of severe ovarian hyperstimulation syndrome after GnRH agonist/HMG superovulation for in-vitro fertilization</TI>
<SO>Human Reproduction</SO>
<YR>1990</YR>
<VL>5</VL>
<NO>8</NO>
<PG>933-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Tan-1992" NAME="Tan 1992" NOTES="&lt;p&gt;Tan SL, Balen A, el Hussein E, Mills C, Campbell S, Yovich J, Jacobs HS. A prospective randomized study of the optimum timing of human chorionic gonadotropin administration after pituitary desensitization in in vitro fertilization. Fertility Sterility 1992;57(6):1259-64.&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Tan SL, Balen A, el Hussein E, Mills C, Campbell S, Yovich J et al</AU>
<TI>A prospective randomized study of the optimum timing of human chorionic gonadotropin administration after pituitary desensitization in in vitro fertilization</TI>
<SO>Fertility and Sterility</SO>
<YR>1992</YR>
<VL>57</VL>
<NO>6</NO>
<PG>1259-64</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Tan-1994" NAME="Tan 1994" NOTES="&lt;p&gt;Tan SL. Simplifying in-vitro fertilization therapy. Curr Opin Obstet Gynecol 1994;6(2):111-4.&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Tan SL</AU>
<TI>Simplifying in-vitro fertilization therapy</TI>
<SO>Current Opinion in Obstetrics and Gynecology</SO>
<YR>1994</YR>
<VL>6</VL>
<NO>2</NO>
<PG>111-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Thomas-2002" NAME="Thomas 2002" NOTES="&lt;p&gt;Thomas K, Searle T, Quinn A, Wood S, Lewis-Jones I, Kingsland C. The value of routine estradiol monitoring in assisted conception cycles. Acta Obstet Gynecol Scand. 2002;81(6):551-4.&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Thomas K, Searle T, Quinn A, Wood S, Lewis-Jones I, Kingsland C</AU>
<TI>The value of routine estradiol monitoring in assisted conception cycle</TI>
<SO>Acta Obstetricia et Gynecologica Scandinavica</SO>
<YR>2002</YR>
<VL>81</VL>
<NO>6</NO>
<PG>551-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Vandekerckhove-2014" MODIFIED="2014-07-05 23:22:16 +1200" MODIFIED_BY="[Empty name]" NAME="Vandekerckhove 2014" TYPE="JOURNAL_ARTICLE">
<AU>Vandekerckhove F, Gerris J, Vansteelandt S, De Sutter P</AU>
<TI>Adding serum estradiol measurements to ultrasound monitoring does not change the yield of mature oocytes in IVF/ICSI</TI>
<SO>Gynecological Endocrinology</SO>
<YR>2014</YR>
<VL>Epub ahead of print (doi:10.3109/09513590.2014.912267)</VL>
<PG>http://www.ncbi.nlm.nih.gov/pubmed/24811095#</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Vlaisavljevic-1992" NAME="Vlaisavljevic 1992" NOTES="&lt;p&gt;Vlaisavljevic V, Kovacic B, Gavric V. In vitro fertilization program based on programmed cycles monitored by ultrasound only. Int J Gynaecol Obstet. 1992;39(3):227-31.&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Vlaisavljevic V, Kovacic B, Gavric V</AU>
<TI>In vitro fertilization program based on programmed cycles monitored by ultrasound only</TI>
<SO>Journal of the International Federation of Gynaecology and Obstetrics</SO>
<YR>1992</YR>
<VL>39</VL>
<NO>3</NO>
<PG>227-31</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Zimon-2013" MODIFIED="2014-07-05 23:23:11 +1200" MODIFIED_BY="[Empty name]" NAME="Zimon 2013" TYPE="JOURNAL_ARTICLE">
<AU>Zimon A, Lannon B, Sheller S, Sakkas D, Ulrich M, Alper M</AU>
<TI>Venopuncture-free IVF: Measurement of estrogen in controlled ovarian stimulation IVF cycles using a "patient-friendly" saliva-based estradiol assay</TI>
<SO>Fertility and Sterility</SO>
<YR>2013</YR>
<VL>100</VL>
<NO>3 Suppl 1</NO>
<PG>S110</PG>
<CY>Fertility and Sterility. Conference: International Federation of Fertility Societies 21st World Congress on Fertility and Sterility and the 69th Annual Meeting of the American Society for Reproductive Medicine, IFFS-ASRM 2013 Boston, MA United States.</CY>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES/>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2014-08-07 10:39:23 +1200" MODIFIED_BY="Helen E Nagels">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2014-08-07 10:39:23 +1200" MODIFIED_BY="Helen E Nagels" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2014-07-05 22:59:17 +1200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Aguirre-2010">
<CHAR_METHODS MODIFIED="2013-11-18 04:54:46 +1300" MODIFIED_BY="Irene OL Kwan">
<P>Randomisation: randomisation list</P>
<P>Allocation concealment: not reported<BR/>
</P>
<P>Blinding of participants/investigators: no</P>
<P>Blinding of assessors: not reported</P>
<P>Number randomised: 70<BR/>Number analysed: 66<BR/>Intention-to-treat analysis: no<BR/>Power and sample calculation not reported<BR/>Duration of study: conducted from January 2006 to June 2007</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-09-07 00:23:12 +1200" MODIFIED_BY="Irene OL Kwan">
<P>Women undergoing IVF, between 25 to 36 years of age with normal follicular reserve, BMI and with less than 3 previous IVF cycles<BR/>Mean age: 32-33 years<BR/>Cause of infertility: female factors, male factors, mixed factors, unexplained<BR/>Similar demographic and infertility characteristics at baseline (age, BMI, basal FSH and causes of infertility)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-12-15 03:58:32 +1300" MODIFIED_BY="Kwan I ">
<P>1. Control: monitoring of ovarian induction by TVUS plus serum estradiol determination (n=31)</P>
<P>2. Intervention: monitoring of ovarian induction by TVUS only (n=35)</P>
<P>Ovarian stimulation protocol: GnRH agonist, triptorelin, followed by rFSH</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-07-05 22:59:17 +1200" MODIFIED_BY="[Empty name]">
<P>1. Primary: live birth rate not reported<BR/>2. Secondary: clinical pregnancy rate/woman, multiple pregnancy rate/woman, number of oocytes retrieved/woman, number of cases of OHSS</P>
<P>Other outcomes reported: ICSI; fertilisation rate, implantation rate, miscarriage rate, ectopic pregnancy rate, number of embryos transferred</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-03-13 13:42:46 +1300" MODIFIED_BY="Kwan I ">
<P>Country: Spain</P>
<P>Single centre</P>
<P>Unidad de Reproduccion Asistida Clinica Montpellier, Espana</P>
<P>Funding: Schering Plough<BR/>Definition of pregnancy not documented</P>
<P>Definition of OHSS not reported</P>
<P>Four women excluded due to non-adherence to treatment protocol</P>
<P>Number of cycles: 42 cycles for control group; 48 cycles for intervention group</P>
<P>Paper in Spanish</P>
<P>Author contacted: no response and no data details were available</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-07-05 23:00:36 +1200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Golan-1994">
<CHAR_METHODS MODIFIED="2013-11-18 04:55:01 +1300" MODIFIED_BY="Irene OL Kwan">
<P>Randomisation: methods unclear</P>
<P>Allocation concealment: methods unclear<BR/>
</P>
<P>Blinding of participants/investigators: patients not blind</P>
<P>Blinding of assessors: yes</P>
<P>Number randomised: 114<BR/>Number analysed: 114<BR/>Intention-to-treat analysis: yes<BR/>Power and sample calculation not reported<BR/>Duration of study: not stated</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-11-18 05:02:55 +1300" MODIFIED_BY="Irene OL Kwan">
<P>Women admitted for first IVF attempts<BR/>Mean age: 30-31 years<BR/>Cause of infertility: tubal disease, male factor, endometriosis, unexplained<BR/>Similar demographic and infertility characteristics at baseline (age, mean duration of infertility, and indications for IVF treatment)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-07-05 23:00:16 +1200" MODIFIED_BY="[Empty name]">
<P>1. Control: monitoring of ovarian induction by TVUS plus serum estradiol determination (n=57)</P>
<P>2. Intervention: monitoring of ovarian induction by TVUS only (n=57)</P>
<P>Ovarian stimulation protocol: human menopausal gonadotrophin (hMG), adjusting dose according to individual response</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-07-05 23:00:36 +1200" MODIFIED_BY="[Empty name]">
<P>1. Primary: live birth rate not reported<BR/>2. Secondary: pregnancy rate/oocyte retrieval, number of oocytes retrieved/woman, number of cases of OHSS, costs saved</P>
<P>Other outcomes reported: duration of hMG treatment, number of hMG ampoules used, serum estradiol, embryos achieved, number of embryo replaced</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-03-13 13:42:05 +1300" MODIFIED_BY="Kwan I ">
<P>Country: Israel</P>
<P>Single centre</P>
<P>Assaf Harofeh Medical Centre, affiliated to Sackler Faculty of Medicine, Tel Aviv University, Israel</P>
<P>Funding: not stated<BR/>Definition of pregnancy not documented</P>
<P>Definition of OHSS not reported</P>
<P>Number of cycles not reported</P>
<P>Author contacted: responded that no further data details were available</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-08-07 10:38:30 +1200" MODIFIED_BY="Helen E Nagels" STUDY_ID="STD-Lass-2003">
<CHAR_METHODS MODIFIED="2014-07-05 23:01:11 +1200" MODIFIED_BY="[Empty name]">
<P>Randomisation: computer-generated randomisation</P>
<P>Allocation concealment: individual sealed envelopes with unique identification<BR/>
</P>
<P>Blinding of participants/investigators: patient-blind</P>
<P>Blinding of assessors: no</P>
<P>Number randomised: 297<BR/>Number analysed: 288<BR/>Intention-to-treat analysis: no<BR/>Power and sample calculation described<BR/>Duration of study: one cycle only</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-03-13 13:40:28 +1300" MODIFIED_BY="Kwan I ">
<P>Women undergoing IVF treatment who had no more than 3 previous unsuccessful attempts; women with PCOS were included; ICSI excluded<BR/>Mean age: 23-39 years<BR/>Cause of infertility: not reported</P>
<P>
<BR/>Similar demographic and infertility characteristics at baseline (age, BMI, duration of infertility and no. of previous ART treatments)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-07-05 23:01:30 +1200" MODIFIED_BY="[Empty name]">
<P>1. Control: monitoring of ovarian induction by TVUS plus serum estradiol determination (n=148)<BR/>2. Intervention: monitoring of ovarian induction by TVUS only (n=149)</P>
<P>Ovarian stimulation protocol: pituitary down-regulation achieved by daily injection of buserelin; recombinant human FSH dose according to clinical practice<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-03-16 05:05:51 +1300" MODIFIED_BY="Kwan I ">
<P>1. Primary: livebirth rate not reported<BR/>2. Secondary: clinical pregnancy rate/woman, number of oocytes retrieved/woman, number of cases of OHSS</P>
<P>Other outcomes reported: dose of Gonal-F, endometrial thickness, number of follicles, number of embryos transferred</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-08-07 10:38:30 +1200" MODIFIED_BY="Helen E Nagels">
<P>Country: UK</P>
<P>Multi-centres: 4 assisted conception units</P>
<P>Bourn Hall Clinic, Cambridge, UK</P>
<P>Funding: author worked for Serono<BR/>Definition of pregnancy: 'a pregnancy in which a fetal sac (with or without fetal heart activity) was visualized by ultrasound on day 28-42 after hCG administration.'</P>
<P>Definition of OHSS: not reported</P>
<P>Nine women had their treatment discontinued due to the risk of OHSS, three from the estradiol plus ultrasound group and five from the ultrasound-only group</P>
<P>A total of 42 women (14.1%) did not reach the embryo transfer stage, 19 in control group and 23 in intervention group, reasons for discontinuing treatment did not differ between the two groups</P>
<P>One cycle only</P>
<P>Author contacted: no response and no data details were available</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-08-07 10:38:56 +1200" MODIFIED_BY="Helen E Nagels" STUDY_ID="STD-Rongieres-2006">
<CHAR_METHODS MODIFIED="2013-11-18 04:54:13 +1300" MODIFIED_BY="Irene OL Kwan">
<P>Randomisation: by 'drawing of lots'</P>
<P>Allocation concealment: methods unclear<BR/>
</P>
<P>Blinding of participants/investigators: not reported</P>
<P>Blinding of assessors: not reported</P>
<P>Number randomised: 185<BR/>Number analysed: 185<BR/>Intention-to-treat analysis: yes<BR/>Power and sample calculation: not described<BR/>Duration of study: not reported</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-07-05 23:02:37 +1200" MODIFIED_BY="[Empty name]">
<P>Women undergoing IVF and ICST treatment; women with previous serious OHSS excluded<BR/>Mean age: 24-42 years<BR/>Cause of infertility: not reported</P>
<P>
<BR/>Similar demographic at baseline (age, BMI, techniques (IVF, ICSI, TESSA))</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-08-01 13:36:30 +1200" MODIFIED_BY="Helen E Nagels">
<P>1. Control: monitoring of ovarian induction by TVUS plus serum estradiol determination (n=97)<BR/>2. Intervention: monitoring of ovarian induction by TVUS only (n=88)</P>
<P>Ovarian stimulation protocol: GnRH agonist long protocol. 35% to 36% of the women also received GnRH antagonists depending on predefined criteria of estradiol level or presence of one follicle &#8805; 13 mm</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-07-05 23:02:50 +1200" MODIFIED_BY="[Empty name]">
<P>1. Primary: live birth rate not reported<BR/>2. Secondary: clinical pregnancy rate/woman, number of oocytes retrieved/woman, rate of cycle cancellation/woman, number of cases of OHSS</P>
<P>Other outcomes reported: units of GnRH used, fertilisation rate</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-08-07 10:38:56 +1200" MODIFIED_BY="Helen E Nagels">
<P>Country: France</P>
<P>Single centre</P>
<P>Centre d'Assistance Médicale à la Procréation, Centre Hospitalier Universitaire, Strasbourg</P>
<P>Funding: not reported<BR/>Definition of pregnancy: 'presence of an intra-uterine gestational sac at US'</P>
<P>Definition of OHSS: not stated</P>
<P>Number of cycles: 1.8±1.2 (control), 1.2±1.4 (intervention)</P>
<P>Author contacted: no response and data details were available</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-07-05 23:03:56 +1200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Strawn-2007">
<CHAR_METHODS MODIFIED="2013-11-18 04:55:55 +1300" MODIFIED_BY="Irene OL Kwan">
<P>Randomisation: methods unclear</P>
<P>Allocation concealment: methods unclear<BR/>
</P>
<P>Blinding of participants/investigators: not reported</P>
<P>Blinding of assessors: not reported</P>
<P>Number randomised: 50<BR/>Number analysed: 49<BR/>Intention-to-treat analysis: no<BR/>Power and sample calculation not described<BR/>Duration of study: not reported</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-11-09 05:47:24 +1300" MODIFIED_BY="Irene OL Kwan">
<P>Women undergoing IVF treatment<BR/>Mean age: 32 years<BR/>Cause of infertility: not reported</P>
<P>
<BR/>Similar demographic characteristics at baseline (weight and BMI)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-12-15 04:01:00 +1300" MODIFIED_BY="Irene OL Kwan">
<P>1. Control: monitoring of ovarian induction by TVUS plus estradiol assay (n=25)<BR/>2. Intervention: monitoring of ovarian induction by TVUS only (n=24)</P>
<P>Ovarian stimulation protocol: based on practitioner preference, no details given</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-07-05 23:03:56 +1200" MODIFIED_BY="[Empty name]">
<P>1. Primary: live birth rate not reported<BR/>2. Secondary: ongoing pregnancy rate/cycle, number of oocytes retrieved/woman, cycle cancellation rate/woman, number of cases of OHSS</P>
<P>Other outcomes reported: number of units of hMG used, level of estradiol, number of embryos transferred</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-03-13 13:43:36 +1300" MODIFIED_BY="Irene OL Kwan">
<P>Country: US</P>
<P>Funding: Azko-Nobel Pharamceutical corporation<BR/>Definition of pregnancy: not reported</P>
<P>Number of cycles: not reported</P>
<P>One cycle was cancelled in the TVUS arm and one cycle cancelled in the estradiol plus TVUS arm</P>
<P>Author contacted: no response and no data details were available</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-08-07 10:39:23 +1200" MODIFIED_BY="Helen E Nagels" STUDY_ID="STD-Wiser-2012">
<CHAR_METHODS MODIFIED="2013-11-18 04:56:16 +1300" MODIFIED_BY="Irene OL Kwan">
<P>Randomisation: computer-generated</P>
<P>Allocation concealment: sealed envelopes<BR/>
</P>
<P>Blinding of participants/investigators: not reported</P>
<P>Blinding of assessors: not reported</P>
<P>Number randomised: 65<BR/>Number analysed: 63<BR/>Intention-to-treat analysis: no<BR/>Power and sample calculation not reported<BR/>Duration of study: conducted from 2007 to 2009</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-07-05 23:04:40 +1200" MODIFIED_BY="[Empty name]">
<P>Women undergoing first IVF attempts, younger than age 40 years<BR/>Mean age: 31-32 years<BR/>Cause of infertility: male factor, PCOS, endometriosis, mechanical, unexplained</P>
<P>Similar demographic and infertility characteristics at baseline (age, BMI, basal FSH, causes of infertility and ovarian reserve)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-07-05 23:05:01 +1200" MODIFIED_BY="[Empty name]">
<P>1. Control: monitoring of ovarian induction by TVUS plus serum estradiol and progesterone determination (n=30)<BR/>2. Intervention: monitoring of ovarian induction by TVUS only (n=33)</P>
<P>Ovarian stimulation protocol: either long GnRH agonist protocol or antagonist protocol as determined by the physician</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-07-05 23:05:16 +1200" MODIFIED_BY="[Empty name]">
<P>1. Primary: live birth rate not reported<BR/>2. Secondary: clinical pregnancy rate/woman, number of oocytes retrieved/woman; number of cases of OHSS</P>
<P>Other outcomes reported: number of induction days, number of gonadotrophin ampoules used, endometrial thickness, estradiol levels, number of embryos transferred, mean score of leading embryos transferred</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-08-07 10:39:23 +1200" MODIFIED_BY="Helen E Nagels">
<P>Country: Israel</P>
<P>Single centre</P>
<P>Meir Medical Center, Kfar Saba, affiliated to Sackler Faculty of Medicine, Tel Aviv University, Israel</P>
<P>Funding: not stated (authors declared no conflict of interest)<BR/>Definition of clinical pregnancy: confirmed by 'by a fetal heartbeat determined by transvaginal ultrasound approximately 32 days after embryo transfer.'</P>
<P>Definition of OHSS: not reported</P>
<P>One patient (in the control group) was cancelled due to insufficient response to treatment</P>
<P>Number of cycles not reported</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>TVUS - Transvaginal ultrasonography; OHSS - Ovarian hyperstimulation syndrome; ICSI - Intra-cytoplasmic sperm injection; TESE: Testicular sperm extraction; hMG - Human menopausal gonadotrophin; hCG - Human chorionic gonadotrophin; GnRH - Gonadotropin-releasing hormone; FSH - Follicle stimulating hormone; PCOS - Polycystic ovary syndrome; BMI - body mass index</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2014-07-05 23:07:55 +1200" MODIFIED_BY="[Empty name]" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2013-11-18 02:52:26 +1300" MODIFIED_BY="Irene OL Kwan" STUDY_ID="STD-Kably-Ambe-1994">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-11-18 02:52:26 +1300" MODIFIED_BY="Irene OL Kwan">
<P>This is a non-randomised trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-12-15 04:01:30 +1300" MODIFIED_BY="Irene OL Kwan" STUDY_ID="STD-Raine_x002d_Fenning-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-12-15 04:01:30 +1300" MODIFIED_BY="Irene OL Kwan">
<P>The intervention comprises estradiol measurement plus two-dimensional ultrasound versus estradiol measurement plus SonoAVC (three-dimensional ultrasound) and does not satisfy the inclusion criteria of the review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-07-05 23:07:55 +1200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Schindler-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-07-05 23:07:55 +1200" MODIFIED_BY="[Empty name]">
<P>This is a quasi-randomised trial in which women were randomised by month of birth</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2014-07-05 23:06:19 +1200" MODIFIED_BY="[Empty name]">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2014-07-05 23:03:22 +1200" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-03-17 04:44:14 +1300" MODIFIED_BY="Irene OL Kwan" RESULT="YES" STUDY_ID="STD-Aguirre-2010">
<DESCRIPTION>
<P>Randomisation list, no details given</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-03-17 04:56:02 +1300" MODIFIED_BY="Irene OL Kwan" RESULT="UNKNOWN" STUDY_ID="STD-Golan-1994">
<DESCRIPTION>
<P>Patients were randomly divided into 2 groups, no details given</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-03-17 04:58:07 +1300" MODIFIED_BY="Kwan I " RESULT="YES" STUDY_ID="STD-Lass-2003">
<DESCRIPTION>
<P>Computer-generated randomisation list</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-07-05 23:03:22 +1200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Rongieres-2006">
<DESCRIPTION>
<P>'Drawing of lots', no details</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-03-25 12:04:50 +1300" MODIFIED_BY="Irene OL Kwan" RESULT="UNKNOWN" STUDY_ID="STD-Strawn-2007">
<DESCRIPTION>
<P>Methods unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-03-17 04:53:33 +1300" MODIFIED_BY="Irene OL Kwan" RESULT="YES" STUDY_ID="STD-Wiser-2012">
<DESCRIPTION>
<P>Computer-generated random numbers</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2014-04-10 17:30:04 +1200" MODIFIED_BY="Kwan I " NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-08 21:00:38 +1200" MODIFIED_BY="Irene OL Kwan" RESULT="UNKNOWN" STUDY_ID="STD-Aguirre-2010">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-08 21:01:17 +1200" MODIFIED_BY="Irene OL Kwan" RESULT="UNKNOWN" STUDY_ID="STD-Golan-1994">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-03-17 04:59:15 +1300" MODIFIED_BY="Kwan I " RESULT="UNKNOWN" STUDY_ID="STD-Lass-2003">
<DESCRIPTION>
<P>Randomisation code for each patient provided in Individual sealed envelopes with unique ID</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-08 21:01:55 +1200" MODIFIED_BY="Irene OL Kwan" RESULT="UNKNOWN" STUDY_ID="STD-Rongieres-2006">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-08 21:02:12 +1200" MODIFIED_BY="Irene OL Kwan" RESULT="UNKNOWN" STUDY_ID="STD-Strawn-2007">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-10 17:30:04 +1200" MODIFIED_BY="Irene OL Kwan" RESULT="UNKNOWN" STUDY_ID="STD-Wiser-2012">
<DESCRIPTION>
<P>Each patient chose a sealed envelope containing the randomised assignment to either the study or the control group</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2014-03-25 12:33:50 +1300" MODIFIED_BY="Kwan I " NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-03-17 04:50:12 +1300" MODIFIED_BY="Irene OL Kwan" RESULT="UNKNOWN" STUDY_ID="STD-Aguirre-2010">
<DESCRIPTION>
<P>Blinding of participants and assessors not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-03-17 04:50:00 +1300" MODIFIED_BY="Kwan I " RESULT="YES" STUDY_ID="STD-Golan-1994">
<DESCRIPTION>
<P>Both control and intervention groups received ultrasonography and serum estradiol measurement, the results were only made known to the clinicians following oocyte retrieval</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-08-17 00:15:17 +1200" MODIFIED_BY="Irene OL Kwan" RESULT="UNKNOWN" STUDY_ID="STD-Lass-2003">
<DESCRIPTION>
<P>Participants blind </P>
<P>Blinding of assessors not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-03-25 12:33:50 +1300" MODIFIED_BY="Irene OL Kwan" RESULT="UNKNOWN" STUDY_ID="STD-Rongieres-2006">
<DESCRIPTION>
<P>Blinding of participants and assessors not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-03-17 04:49:16 +1300" MODIFIED_BY="Irene OL Kwan" RESULT="UNKNOWN" STUDY_ID="STD-Strawn-2007">
<DESCRIPTION>
<P>Blinding of participants and assessors not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-03-17 04:49:05 +1300" MODIFIED_BY="Irene OL Kwan" RESULT="UNKNOWN" STUDY_ID="STD-Wiser-2012">
<DESCRIPTION>
<P>Blinding of participants and assessors not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="GROUP" NO="7">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" NO="8">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2014-07-05 23:06:19 +1200" MODIFIED_BY="[Empty name]" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-08-13 02:20:45 +1200" MODIFIED_BY="Kwan I " RESULT="UNKNOWN" STUDY_ID="STD-Aguirre-2010">
<DESCRIPTION>
<P>Four women excluded due to non-adherence to treatment protocol</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-06-24 20:52:47 +1200" MODIFIED_BY="Kwan I " RESULT="YES" STUDY_ID="STD-Golan-1994">
<DESCRIPTION>
<P>All women randomised included in analysis</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-09-10 00:04:07 +1200" MODIFIED_BY="Kwan I " RESULT="UNKNOWN" STUDY_ID="STD-Lass-2003">
<DESCRIPTION>
<P>A total of 9 women (3%) did not complete study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-06-24 20:51:48 +1200" MODIFIED_BY="Irene OL Kwan" RESULT="YES" STUDY_ID="STD-Rongieres-2006">
<DESCRIPTION>
<P>All women randomised included in analysis</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-12-15 04:01:10 +1300" MODIFIED_BY="Irene OL Kwan" RESULT="UNKNOWN" STUDY_ID="STD-Strawn-2007">
<DESCRIPTION>
<P>one cycle was cancelled in the TVUS arm and one cycle cancelled in the estradiol plus TVUS arm</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-07-05 23:06:19 +1200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Wiser-2012">
<DESCRIPTION>
<P>Two patients excluded after randomisation: one woman conceived spontaneously under suppression with GnRH agonist and one left the clinic before starting treatment</P>
<P>One woman (in the control group) was cancelled due to insufficient response to treatment, results did not reflect this</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" MODIFIED="2014-03-09 07:31:35 +1300" MODIFIED_BY="Kwan I " NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-08-13 02:10:55 +1200" MODIFIED_BY="Kwan I " RESULT="YES" STUDY_ID="STD-Aguirre-2010">
<DESCRIPTION>
<P>All pre-specified outcomes reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-08-10 02:16:09 +1200" MODIFIED_BY="Irene OL Kwan" RESULT="YES" STUDY_ID="STD-Golan-1994">
<DESCRIPTION>
<P>All pre-specified outcomes reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-08-13 00:24:16 +1200" MODIFIED_BY="Kwan I " RESULT="YES" STUDY_ID="STD-Lass-2003">
<DESCRIPTION>
<P>All pre-specified outcomes reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-09 05:43:31 +1300" MODIFIED_BY="Irene OL Kwan" RESULT="UNKNOWN" STUDY_ID="STD-Rongieres-2006">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-09 05:39:34 +1300" MODIFIED_BY="Irene OL Kwan" RESULT="UNKNOWN" STUDY_ID="STD-Strawn-2007">
<DESCRIPTION>
<P>Not clear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-08-13 00:19:06 +1200" MODIFIED_BY="Kwan I " RESULT="YES" STUDY_ID="STD-Wiser-2012">
<DESCRIPTION>
<P>All pre-specified outcomes reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" MODIFIED="2014-03-23 01:37:26 +1300" MODIFIED_BY="Kwan I " NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-08-13 02:10:53 +1200" MODIFIED_BY="Kwan I " RESULT="YES" STUDY_ID="STD-Aguirre-2010">
<DESCRIPTION>
<P>Comparable demographic and infertility characteristics at baseline</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-08-10 02:16:43 +1200" MODIFIED_BY="Irene OL Kwan" RESULT="YES" STUDY_ID="STD-Golan-1994">
<DESCRIPTION>
<P>Comparable demographic and infertility characteristics at baseline</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-08-17 00:18:09 +1200" MODIFIED_BY="Irene OL Kwan" RESULT="UNKNOWN" STUDY_ID="STD-Lass-2003">
<DESCRIPTION>
<P>Causes of infertility not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-09 05:48:09 +1300" MODIFIED_BY="Irene OL Kwan" RESULT="UNKNOWN" STUDY_ID="STD-Rongieres-2006">
<DESCRIPTION>
<P>Causes of infertility not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-12-02 06:50:12 +1300" MODIFIED_BY="Irene OL Kwan" RESULT="UNKNOWN" STUDY_ID="STD-Strawn-2007">
<DESCRIPTION>
<P>Causes of infertility not reported; stimulation protocol based on practitioner preference</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-03-23 01:37:26 +1300" MODIFIED_BY="Kwan I " RESULT="UNKNOWN" STUDY_ID="STD-Wiser-2012">
<DESCRIPTION>
<P>Comparable demographic and infertility characteristics at baseline, stimulation protocols varied as determined by the physician</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES MODIFIED="2014-07-05 23:08:59 +1200" MODIFIED_BY="[Empty name]">
<SOF_TABLE ID="SOF-01" MODIFIED="2014-07-05 23:08:59 +1200" MODIFIED_BY="[Empty name]" NO="1" READONLY="YES">
<TITLE MODIFIED="2014-01-12 06:16:15 +1300" MODIFIED_BY="Grade Profiler">Monitoring ovarian stimulation by transvaginal ultrasound (TVUS) only compared to monitoring with TVUS plus serum estradiol for women undergoing ovarian stimulation with gonadotrophins in IVF and ICSI procedures</TITLE>
<TABLE COLS="7" ROWS="12">
<TR>
<TD COLSPAN="7">
<P>
<B>Monitoring ovarian stimulation by transvaginal ultrasound (TVUS) only compared to monitoring with TVUS plus serum estradiol for women undergoing ovarian stimulation with gonadotrophins in IVF and ICSI procedures</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Population:</B> Women undergoing ovarian stimulation with gonadotrophins in IVF and ICSI procedures<BR/>
<B>Settings:</B> Hospital or outpatient assisted reproduction units<BR/>
<B>Intervention:</B> Monitoring ovarian stimulation by transvaginal ultrasound (TVUS) only<BR/>
<B>Comparison: </B>Monitoring with TVUS plus serum estradiol</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>No of participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Assumed risk</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Monitoring with TVUS plus serum estradiol</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Monitoring by TVUS only</B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Live birth per woman</B>
</P>
</TD>
<TD COLSPAN="6" ROWSPAN="1" VALIGN="TOP">
<P>No evidence available, as none of the included studies reported live birth as an outcome</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Clinical pregnancy per woman</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>337 per 1000</B>
</P>
<P/>
<P/>
<P/>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>361 per 1000</B>
<BR/>(287 to 439)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>OR 1.05 </B>
<BR/>(0.79 to 1.54)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>617<BR/>(4 studies)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>1,6</SUP>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>No difference demonstrated between monitoring by TVUS only and TVUS plus serum estradiol</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Mean number of oocytes retrieved per woman</B>
</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1" VALIGN="TOP">
<P>The mean number of oocytes retrieved per woman in the intervention groups was<BR/>
<B>0.32 higher </B>(0.6 lower to 1.24 higher)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>595<BR/>(5 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>2,7</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>No difference demonstrated between monitoring by TVUS only and TVUS plus serum estradiol</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Cycle cancellation rate per woman</B>
</P>
<P/>
</TD>
<TD>
<P>
<B>36 per 1000</B>
</P>
<P/>
</TD>
<TD>
<P>
<B>17 per 1000</B>
</P>
<P>(3 to 140)</P>
</TD>
<TD>
<P>
<B>OR 0.57</B>
</P>
<P>(0.07 to 4.39)</P>
</TD>
<TD>
<P>115</P>
<P>(2 studies)</P>
</TD>
<TD>
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>3,6</SUP>
</P>
</TD>
<TD>
<P>No difference demonstrated between monitoring by TVUS only and TVUS plus serum estradiol</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>OHSS rate (mild, moderate or severe) per woman</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>36 per 1000</B>
</P>
<P/>
<P/>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>36 per 1000</B>
<BR/>(18 to 75)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>OR 1.03 </B>
<BR/>(0.48 to 2.20)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>781<BR/>(6 studies)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>4,5,6</SUP>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>No difference demonstrated between monitoring by TVUS only and TVUS plus serum estradiol</P>
<P/>
<P>Two studies reported no incidence of OHSS</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk is</B> the median control group risk across studies. The <B>corresponding risk</B> (and its 95% CI) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>CI:</B> Confidence interval; <B>RR:</B> Risk ratio; <B>OR:</B> Odds ratio</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP> Methods of allocation concealment inadequately described in the four trials; none of the trials adequately described blinding<BR/>
<SUP>2</SUP> Inadequate description of methods of randomisation in two of the five trials, allocation concealment all of the five trials and blinding in four of the five trials</P>
<P>
<SUP>3 </SUP>Methods of randomisation and allocation concealment inadequately described in one of the two trials<BR/>
<SUP>4 </SUP>Methods of randomisation inadequately described in three of the six trials, allocation concealment inadequately described in all the six trials and blinding inadequately described in five of the six trials<BR/>
<SUP>5 </SUP>No definition of OHSS provided by authors of these 6 studies</P>
<P>
<SUP>6</SUP> Serious imprecision with wide confidence intervals</P>
<P>7 Unclear whether mean values correctly calculated (i.e. whether they include zero counts for cancelled cycles)</P>
</FOOTNOTES>
</SOF_TABLE>
</SOF_TABLES>
<ADDITIONAL_TABLES MODIFIED="2013-10-07 05:32:57 +1300" MODIFIED_BY="Irene OL Kwan"/>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2014-08-06 17:19:26 +1200" MODIFIED_BY="Helen E Nagels">
<COMPARISON ID="CMP-001" MODIFIED="2014-08-06 17:19:26 +1200" MODIFIED_BY="Helen E Nagels" NO="1">
<NAME>Ultrasound only versus ultrasound plus estradiol</NAME>
<DICH_OUTCOME CHI2="3.1700113510727435" CI_END="1.536791632027897" CI_START="0.7882941275793462" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="OR" EFFECT_SIZE="1.1006560856328695" ESTIMABLE="YES" EVENTS_1="110" EVENTS_2="105" I2="5.363114899106307" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="0.18661498708658672" LOG_CI_START="-0.10331170871478282" LOG_EFFECT_SIZE="0.04165163918590193" METHOD="MH" MODIFIED="2014-08-01 14:01:44 +1200" MODIFIED_BY="Helen E Nagels" NO="1" P_CHI2="0.3661485510840029" P_Q="1.0" P_Z="0.5733346124895027" Q="0.0" RANDOM="NO" SCALE="2.4720247931100507" SORT_BY="EFFECT_SIZE" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="305" TOTAL_2="312" WEIGHT="100.0" Z="0.563147263661116">
<NAME>Clinical pregnancy per woman</NAME>
<GROUP_LABEL_1>Ultrasound only</GROUP_LABEL_1>
<GROUP_LABEL_2>Ultrasound + estradiol</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours US only</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours US + estradiol</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.4990829096714884" CI_START="0.5650638273732417" EFFECT_SIZE="0.9203681472589036" ESTIMABLE="YES" EVENTS_1="46" EVENTS_2="49" LOG_CI_END="0.1758256530064391" LOG_CI_START="-0.24790249322415342" LOG_EFFECT_SIZE="-0.03603842010885713" MODIFIED="2014-04-30 22:43:12 +1200" MODIFIED_BY="Irene OL Kwan" ORDER="94259" O_E="0.0" SE="0.24890001058400174" STUDY_ID="STD-Lass-2003" TOTAL_1="148" TOTAL_2="149" VAR="0.061951215268716185" WEIGHT="51.225204857095434"/>
<DICH_DATA CI_END="1.7559679546698723" CI_START="0.4995210874902465" EFFECT_SIZE="0.9365591397849462" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="30" LOG_CI_END="0.24451658603646545" LOG_CI_START="-0.3014461731290093" LOG_EFFECT_SIZE="-0.02846479354627193" MODIFIED="2013-11-10 05:14:55 +1300" MODIFIED_BY="Irene OL Kwan" ORDER="16" O_E="0.0" SE="0.320701227293044" STUDY_ID="STD-Rongieres-2006" TOTAL_1="88" TOTAL_2="97" VAR="0.10284927718726468" WEIGHT="30.60448792182458"/>
<DICH_DATA CI_END="4.598740287602032" CI_START="0.6899392799053785" EFFECT_SIZE="1.78125" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="14" LOG_CI_END="0.662638883623571" LOG_CI_START="-0.16118912891840023" LOG_EFFECT_SIZE="0.2507248773525854" MODIFIED="2014-04-30 22:48:02 +1200" MODIFIED_BY="Irene OL Kwan" ORDER="10" O_E="0.0" SE="0.4839206525815854" STUDY_ID="STD-Aguirre-2010" TOTAL_1="35" TOTAL_2="35" VAR="0.23417919799498746" WEIGHT="9.740783252537717"/>
<DICH_DATA CI_END="5.39873664241916" CI_START="0.7450359876449523" EFFECT_SIZE="2.0055555555555555" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="12" LOG_CI_END="0.7322921425233342" LOG_CI_START="-0.12782274891863052" LOG_EFFECT_SIZE="0.3022346968023519" MODIFIED="2014-04-30 22:48:11 +1200" MODIFIED_BY="Irene OL Kwan" ORDER="11" O_E="0.0" SE="0.505235744870389" STUDY_ID="STD-Wiser-2012" TOTAL_1="34" TOTAL_2="31" VAR="0.25526315789473686" WEIGHT="8.429523968542254"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="4.8465873838214" CI_END="1.2436050075646827" CI_START="-0.5980318753521308" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="MD" EFFECT_SIZE="0.32278656610627604" ESTIMABLE="YES" I2="17.46770081248157" I2_Q="0.0" ID="CMP-001.02" MODIFIED="2014-08-06 17:19:23 +1200" MODIFIED_BY="Helen E Nagels" NO="2" P_CHI2="0.3034041371496857" P_Q="1.0" P_Z="0.4920500387993135" Q="0.0" RANDOM="NO" SCALE="8.78980588307797" SORT_BY="EFFECT_SIZE" STUDIES="5" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="299" TOTAL_2="297" UNITS="" WEIGHT="100.0" Z="0.6870518831699952">
<NAME>Mean number of oocytes retrieved per woman</NAME>
<GROUP_LABEL_1>Ultrasound only</GROUP_LABEL_1>
<GROUP_LABEL_2>Ultrasound + estradiol</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours US only</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours US + estradiol</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.729407436616988" CI_START="-2.729407436616988" EFFECT_SIZE="-1.0" ESTIMABLE="YES" MEAN_1="9.9" MEAN_2="10.9" MODIFIED="2014-04-30 23:10:15 +1200" MODIFIED_BY="Irene OL Kwan" ORDER="12" SD_1="3.1" SD_2="4.2" SE="0.8823669466675578" STUDY_ID="STD-Aguirre-2010" TOTAL_1="35" TOTAL_2="35" WEIGHT="28.35002019265967"/>
<CONT_DATA CI_END="1.664864439425757" CI_START="-1.0648644394257591" EFFECT_SIZE="0.29999999999999893" ESTIMABLE="YES" MEAN_1="11.7" MEAN_2="11.4" MODIFIED="2014-04-30 23:10:35 +1200" MODIFIED_BY="Irene OL Kwan" ORDER="94261" SD_1="5.9" SD_2="6.1" SE="0.696372203872946" STUDY_ID="STD-Lass-2003" TOTAL_1="148" TOTAL_2="149" WEIGHT="45.51651257591362"/>
<CONT_DATA CI_END="5.01353310084274" CI_START="-1.6135331008427416" EFFECT_SIZE="1.6999999999999993" ESTIMABLE="YES" MEAN_1="11.7" MEAN_2="10.0" MODIFIED="2014-04-30 23:11:10 +1200" MODIFIED_BY="Irene OL Kwan" ORDER="13" SD_1="8.0" SD_2="5.5" SE="1.6906091780152426" STUDY_ID="STD-Wiser-2012" TOTAL_1="34" TOTAL_2="31" WEIGHT="7.722632886434852"/>
<CONT_DATA CI_END="4.623394425292021" CI_START="-1.2233944252920188" EFFECT_SIZE="1.700000000000001" ESTIMABLE="YES" MEAN_1="13.4" MEAN_2="11.7" MODIFIED="2013-09-07 02:04:04 +1200" MODIFIED_BY="Irene OL Kwan" ORDER="94260" SD_1="7.5" SD_2="8.4" SE="1.4915551756825034" STUDY_ID="STD-Golan-1994" TOTAL_1="57" TOTAL_2="57" WEIGHT="9.92140522136574"/>
<CONT_DATA CI_END="5.160346964148831" CI_START="-1.1603469641488307" EFFECT_SIZE="2.0" ESTIMABLE="YES" MEAN_1="11.0" MEAN_2="9.0" MODIFIED="2014-04-30 23:11:21 +1200" MODIFIED_BY="Irene OL Kwan" ORDER="14" SD_1="7.0" SD_2="4.0" SE="1.61245154965971" STUDY_ID="STD-Strawn-2007" TOTAL_1="25" TOTAL_2="25" WEIGHT="8.48942912362611"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="1.493489632186949" CI_END="2.1980540951127026" CI_START="0.4816976626203262" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="OR" EFFECT_SIZE="1.0289788724404525" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="14" I2="0.0" I2_Q="0.0" ID="CMP-001.03" LOG_CI_END="0.3420383764040564" LOG_CI_START="-0.31722546104192323" LOG_EFFECT_SIZE="0.012406457681066584" METHOD="MH" MODIFIED="2014-08-06 17:19:26 +1200" MODIFIED_BY="Helen E Nagels" NO="3" P_CHI2="0.6837737610742034" P_Q="1.0" P_Z="0.9411951761640447" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="EFFECT_SIZE" STUDIES="6" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="387" TOTAL_2="394" WEIGHT="100.0" Z="0.07376776595183202">
<NAME>OHSS rate (mild, moderate or severe) per woman</NAME>
<GROUP_LABEL_1>Ultrasound only</GROUP_LABEL_1>
<GROUP_LABEL_2>Ultrasound + estradiol</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours US only</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours US + estradiol</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2014-04-30 23:29:34 +1200" MODIFIED_BY="Irene OL Kwan" ORDER="21" O_E="0.0" SE="0.0" STUDY_ID="STD-Wiser-2012" TOTAL_1="34" TOTAL_2="31" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2014-04-30 23:29:21 +1200" MODIFIED_BY="Irene OL Kwan" ORDER="20" O_E="0.0" SE="0.0" STUDY_ID="STD-Aguirre-2010" TOTAL_1="35" TOTAL_2="35" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="2.263963461777754" CI_START="0.08087779853238819" EFFECT_SIZE="0.42790697674418604" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="5" LOG_CI_END="0.3548694134719099" LOG_CI_START="-1.0921706786120102" LOG_EFFECT_SIZE="-0.36865063257005004" MODIFIED="2014-04-16 08:51:04 +1200" MODIFIED_BY="Irene OL Kwan" ORDER="25" O_E="0.0" SE="0.8499985130540733" STUDY_ID="STD-Rongieres-2006" TOTAL_1="88" TOTAL_2="97" VAR="0.7224974721941355" WEIGHT="35.362780558694595"/>
<DICH_DATA CI_END="16.927920091810748" CI_START="0.059074002864874804" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.2286036002743048" LOG_CI_START="-1.2286036002743048" LOG_EFFECT_SIZE="0.0" MODIFIED="2014-04-30 23:29:46 +1200" MODIFIED_BY="Irene OL Kwan" ORDER="22" O_E="0.0" SE="1.4433756729740645" STUDY_ID="STD-Strawn-2007" TOTAL_1="25" TOTAL_2="25" VAR="2.0833333333333335" WEIGHT="7.30282538049321"/>
<DICH_DATA CI_END="6.363298967429589" CI_START="0.29002198819506403" EFFECT_SIZE="1.3584905660377358" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" LOG_CI_END="0.8036823282110399" LOG_CI_START="-0.5375690745500812" LOG_EFFECT_SIZE="0.1330566268304794" MODIFIED="2013-12-08 14:27:58 +1300" MODIFIED_BY="Irene OL Kwan" ORDER="23" O_E="0.0" SE="0.7878577132834035" STUDY_ID="STD-Golan-1994" TOTAL_1="57" TOTAL_2="57" VAR="0.6207197763801536" WEIGHT="21.21983252007347"/>
<DICH_DATA CI_END="4.610884275696545" CI_START="0.44336214322408546" EFFECT_SIZE="1.4297872340425533" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="5" LOG_CI_END="0.6637842224022091" LOG_CI_START="-0.3532413921659935" LOG_EFFECT_SIZE="0.1552714151181078" MODIFIED="2014-04-30 23:29:57 +1200" MODIFIED_BY="Irene OL Kwan" ORDER="24" O_E="0.0" SE="0.5974058803553474" STUDY_ID="STD-Lass-2003" TOTAL_1="148" TOTAL_2="149" VAR="0.3568937858831476" WEIGHT="36.11456154073873"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.3117466878068912" CI_END="4.393432593269299" CI_START="0.07266219296954908" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="OR" EFFECT_SIZE="0.5650101299010845" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-001.04" LOG_CI_END="0.6428039675767568" LOG_CI_START="-1.1386914991212231" LOG_EFFECT_SIZE="-0.24794376577223307" METHOD="MH" MODIFIED="2014-08-06 17:19:26 +1200" MODIFIED_BY="Helen E Nagels" NO="4" P_CHI2="0.5766104312720196" P_Q="1.0" P_Z="0.5853649416229973" Q="0.0" RANDOM="NO" SCALE="154.40533811435046" SORT_BY="EFFECT_SIZE" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="59" TOTAL_2="56" WEIGHT="100.0" Z="0.5455650718051449">
<NAME>Cycle cancellation rate per woman</NAME>
<GROUP_LABEL_1>Ultrasound only</GROUP_LABEL_1>
<GROUP_LABEL_2>ultrasound + estradiol</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours US only</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours US + estradiol</GRAPH_LABEL_2>
<DICH_DATA CI_END="7.50538753120658" CI_START="0.011570332982875848" EFFECT_SIZE="0.2946859903381642" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8753731214053332" LOG_CI_START="-1.9366541422976347" LOG_EFFECT_SIZE="-0.5306405104461508" MODIFIED="2014-04-30 23:20:07 +1200" MODIFIED_BY="Irene OL Kwan" ORDER="17" O_E="0.0" SE="1.6517987344585736" STUDY_ID="STD-Wiser-2012" TOTAL_1="34" TOTAL_2="31" VAR="2.728439059158945" WEIGHT="61.673221308544875"/>
<DICH_DATA CI_END="16.927920091810748" CI_START="0.059074002864874804" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.2286036002743048" LOG_CI_START="-1.2286036002743048" LOG_EFFECT_SIZE="0.0" MODIFIED="2014-04-30 23:24:47 +1200" MODIFIED_BY="Irene OL Kwan" ORDER="17" O_E="0.0" SE="1.4433756729740645" STUDY_ID="STD-Strawn-2007" TOTAL_1="25" TOTAL_2="25" VAR="2.0833333333333335" WEIGHT="38.32677869145513"/>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2014-08-06 17:19:27 +1200" MODIFIED_BY="Helen E Nagels">
<FIGURE FILENAME="Flowchart.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2014-08-06 15:33:27 +1200" MODIFIED_BY="Helen E Nagels" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Study flow diagram.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAApoAAAKOCAYAAAAGS7lyAABbnUlEQVR42u3dDaRVad8/8IckSRLJ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</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias graph.png" FILE_TYPE="PNG" ID="FIG-02" MODIFIED="2014-07-05 23:06:20 +1200" MODIFIED_BY="[Empty name]" NO="2" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_GRAPH_PLOT">
<CAPTION>
<P>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAiMAAADnCAMAAAD7EqYIAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias summary.png" FILE_TYPE="PNG" ID="FIG-03" MODIFIED="2014-07-05 23:06:20 +1200" MODIFIED_BY="[Empty name]" NO="3" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_TABLE_PLOT">
<CAPTION>
<P>Risk of bias summary: review authors' judgements about each risk of bias item for each included study.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAASYAAAHOCAIAAAC6sTNiAAAUdElEQVR42u3dsa7c1hHG8QsYCFyo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==
</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-04" MODIFIED="2014-08-01 14:01:45 +1200" MODIFIED_BY="Helen E Nagels" NO="4" REF_ID="CMP-001.01" SETTINGS="SHOW_MORE_DECIMALS:NO;SHOW_ROB_TABLE:NO;SHOW_WEIGHT_COLUMN:YES;SHOW_RAW_DATA_COLUMNS:YES;SHOW_EFFECT_SIZE_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 1 Ultrasound only versus ultrasound plus estradiol, outcome: 1.1 Clinical pregnancy per woman.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAA1sAAADACAMAAADFq4kqAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-05" MODIFIED="2014-08-06 17:19:24 +1200" MODIFIED_BY="Helen E Nagels" NO="5" REF_ID="CMP-001.02" SETTINGS="SHOW_MORE_DECIMALS:NO;SHOW_ROB_TABLE:NO;SHOW_WEIGHT_COLUMN:YES;SHOW_RAW_DATA_COLUMNS:YES;SHOW_EFFECT_SIZE_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 1 Ultrasound only versus ultrasound plus estradiol, outcome: 1.2 Mean number of oocytes retrieved per woman.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAA2kAAADACAMAAACprdsvAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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=
</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-06" MODIFIED="2014-08-06 17:19:27 +1200" MODIFIED_BY="Helen E Nagels" NO="6" REF_ID="CMP-001.03" SETTINGS="SHOW_MORE_DECIMALS:NO;SHOW_ROB_TABLE:NO;SHOW_WEIGHT_COLUMN:YES;SHOW_RAW_DATA_COLUMNS:YES;SHOW_EFFECT_SIZE_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 1 Ultrasound only versus ultrasound plus estradiol, outcome: 1.3 OHSS rate (mild, moderate or severe) per woman.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAA1sAAADgCAMAAADCB4wcAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-07" MODIFIED="2014-08-06 17:19:27 +1200" MODIFIED_BY="Helen E Nagels" NO="7" REF_ID="CMP-001.04" SETTINGS="SHOW_MORE_DECIMALS:NO;SHOW_ROB_TABLE:NO;SHOW_WEIGHT_COLUMN:YES;SHOW_RAW_DATA_COLUMNS:YES;SHOW_EFFECT_SIZE_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 1 Ultrasound only versus ultrasound plus estradiol, outcome: 1.4 Cycle cancellation rate per woman.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAA1sAAACgCAMAAADNX4ZwAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK/>
<APPENDICES MODIFIED="2014-07-05 23:24:34 +1200" MODIFIED_BY="[Empty name]">
<APPENDIX ID="APP-01" MODIFIED="2014-07-05 23:24:34 +1200" MODIFIED_BY="[Empty name]" NO="1" NOTES="&lt;p&gt;Keywords CONTAINS &amp;quot;IVF&amp;quot;or &amp;quot;ICSI&amp;quot;or&amp;quot;in vitro fertilisation&amp;quot;or &amp;quot;in vitro fertilization&amp;quot;or &amp;quot;in-vitro fertilisation procedure&amp;quot;or&amp;quot;in-vitro fertilisation techniques&amp;quot;or &amp;quot;intracytoplasmic sperm injection&amp;quot;or &amp;quot;Embryo&amp;quot;or &amp;quot;oocytes&amp;quot;or &amp;quot;ovarian hyperstimulation&amp;quot;or &amp;quot;ovarian hyperstimulation syndrome&amp;quot;or&amp;quot;ovarian stimulation&amp;quot;or&amp;quot;ovarian response&amp;quot;or&amp;quot;ovarian stimulation syndrome&amp;quot;&lt;/p&gt;&lt;p&gt;AND&lt;/p&gt;&lt;p&gt;Keywords CONTAINS &amp;quot;ultrasonography&amp;quot; or &amp;quot;ultrasound&amp;quot; or&amp;quot;ultrasound guidance&amp;quot; or &amp;quot;ultrasound, pelvic&amp;quot; or &amp;quot;monitoring&amp;quot; or Title CONTAINS &amp;quot;ultrasonography&amp;quot; or &amp;quot;ultrasound&amp;quot; or&amp;quot;ultrasound guidance&amp;quot; or &amp;quot;ultrasound, pelvic&amp;quot;or &amp;quot;monitoring&amp;quot;&lt;/p&gt;" NOTES_MODIFIED="2014-07-05 23:24:34 +1200" NOTES_MODIFIED_BY="[Empty name]">
<TITLE MODIFIED="2014-07-05 23:24:34 +1200" MODIFIED_BY="[Empty name]">Menstrual Disorders and Subfertility Group (MDSG) search strategy (20 May 2014)</TITLE>
<APPENDIX_BODY MODIFIED="2013-12-16 14:05:08 +1300" MODIFIED_BY="[Empty name]">
<P>Keywords CONTAINS "IVF"or "ICSI"or"in vitro fertilisation"or "in vitro fertilization"or "in-vitro fertilisation procedure"or"in-vitro fertilisation techniques"or "intracytoplasmic sperm injection"or "Embryo"or "oocytes"or "ovarian hyperstimulation"or "ovarian hyperstimulation syndrome"or"ovarian stimulation"or"ovarian response"or"ovarian stimulation syndrome"</P>
<P>AND</P>
<P>Keywords CONTAINS "ultrasonography" or "ultrasound" or"ultrasound guidance" or "ultrasound, pelvic" or "monitoring" or Title CONTAINS "ultrasonography" or "ultrasound" or"ultrasound guidance" or "ultrasound, pelvic"or "monitoring"</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-02" MODIFIED="2014-05-31 00:50:40 +1200" MODIFIED_BY="Irene OL Kwan" NO="2" NOTES="&lt;p&gt;1 Ovulation Induction/ (881)&lt;/p&gt;&lt;p&gt;2 Ovarian Hyperstimulation Syndrome/ (128)&lt;/p&gt;&lt;p&gt;3 Ovarian Follicle/ (311)&lt;/p&gt;&lt;p&gt;4 Follicle Stimulating Hormone/ (1472)&lt;/p&gt;&lt;p&gt;5 Luteinizing Hormone/ (1383)&lt;/p&gt;&lt;p&gt;6 Gonadotropins/ (182)&lt;/p&gt;&lt;p&gt;7 (ovulat$ adj5 (induct$ or stimulat$)).tw. (571)&lt;/p&gt;&lt;p&gt;8 (ovar$ adj5 (induct$ or stimulat$ or follicle$)).tw. (1043)&lt;/p&gt;&lt;p&gt;9 ((ovar$ or ovulat$) adj5 (hyperstimulat$ or hyper stimulat$ or hyper-stimulat$)).tw. (560)&lt;/p&gt;&lt;p&gt;10 gonadotrop?in$.tw. (2433)&lt;/p&gt;&lt;p&gt;11 (luteiniz$ adj5 hormone$).tw. (1134)&lt;/p&gt;&lt;p&gt;12 (stimulat$ adj5 (cycle$ or hormone$)).tw. (2399)&lt;/p&gt;&lt;p&gt;13 or/1-12 (6027)&lt;/p&gt;&lt;p&gt;14 exp Fertilization in Vitro/ (1464)&lt;/p&gt;&lt;p&gt;15 (IVF or in vitro fertili?ation or in-vitro fertili?ation or in-vitro-fertili?ation).tw. (2483)&lt;/p&gt;&lt;p&gt;16 Intracytoplasmic Sperm Injections/ (330)&lt;/p&gt;&lt;p&gt;17 ((intracytoplasmic or intra-cytoplasmic) adj5 sperm inject$).tw. (433)&lt;/p&gt;&lt;p&gt;18 ICSI.tw. (679)&lt;/p&gt;&lt;p&gt;19 or/14-18 (2975)&lt;/p&gt;&lt;p&gt;20 13 and 19 (1346)&lt;/p&gt;&lt;p&gt;21 (ultrasound or ultrasonograph$ or ultra-sound or ultra-sonograph$).tw. (8250)&lt;/p&gt;&lt;p&gt;22 ((ovar$ or ovulat$) adj5 (monitor$ or scan$ or measur$)).tw. (339)&lt;/p&gt;&lt;p&gt;23 exp Estradiol/ (3203)&lt;/p&gt;&lt;p&gt;24 ((oestrad$ or estrad$) adj5 (monitor$ or scan$ or measur$)).tw. (396)&lt;/p&gt;&lt;p&gt;25 (hormon$ adj5 (measure$ or monitor$ or scan$)).tw. (1350)&lt;/p&gt;&lt;p&gt;26 exp Ultrasonography/ (5903)&lt;/p&gt;&lt;p&gt;27 echograph$.tw. (147)&lt;/p&gt;&lt;p&gt;28 or/21-27 (16609)&lt;/p&gt;&lt;p&gt;29 20 and 28 (440)&lt;/p&gt;&lt;p&gt;30 limit 29 to yr=&amp;quot;2007 -Current&amp;quot; (81)&lt;/p&gt;" NOTES_MODIFIED="2014-05-31 00:50:40 +1200" NOTES_MODIFIED_BY="Irene OL Kwan">
<TITLE MODIFIED="2014-05-31 00:39:54 +1200" MODIFIED_BY="Irene OL Kwan">Cochrane Central Register of Controlled Trials (CENTRAL) search strategy (April 2014)</TITLE>
<APPENDIX_BODY MODIFIED="2014-05-31 00:50:40 +1200" MODIFIED_BY="[Empty name]">
<P>1 Ovulation Induction/ (981)<BR/>2 Ovarian Hyperstimulation Syndrome/ (140)<BR/>3 Ovarian Follicle/ (346)<BR/>4 Follicle Stimulating Hormone/ (1546)<BR/>5 Luteinizing Hormone/ (1451)<BR/>6 Gonadotropins/ (194)<BR/>7 (ovulat$ adj5 (induct$ or stimulat$)).tw. (651)<BR/>8 (ovar$ adj5 (induct$ or stimulat$ or follicle$)).tw. (1225)<BR/>9 ((ovar$ or ovulat$) adj5 (hyperstimulat$ or hyper stimulat$ or hyper-stimulat$)).tw. (620)<BR/>10 gonadotrop?in$.tw. (2694)<BR/>11 (luteiniz$ adj5 hormone$).tw. (1225)<BR/>12 (stimulat$ adj5 (cycle$ or hormone$)).tw. (2651)<BR/>13 or/1-12 (6658)<BR/>14 exp Fertilization in Vitro/ (1609)<BR/>15 (IVF or in vitro fertili?ation or in-vitro fertili?ation or in-vitro-fertili?ation).tw. (2758)<BR/>16 Intracytoplasmic Sperm Injections/ (394)<BR/>17 ((intracytoplasmic or intra-cytoplasmic) adj5 sperm inject$).tw. (516)<BR/>18 ICSI.tw. (801)<BR/>19 or/14-18 (3300)<BR/>20 13 and 19 (1492)<BR/>21 (ultrasound or ultrasonograph$ or ultra-sound or ultra-sonograph$).tw. (10233)<BR/>22 ((ovar$ or ovulat$) adj5 (monitor$ or scan$ or measur$)).tw. (390)<BR/>23 exp Estradiol/ (3362)<BR/>24 ((oestrad$ or estrad$) adj5 (monitor$ or scan$ or measur$)).tw. (437)<BR/>25 (hormon$ adj5 (measure$ or monitor$ or scan$)).tw. (1520)<BR/>26 exp Ultrasonography/ (6733)<BR/>27 echograph$.tw. (160)<BR/>28 or/21-27 (19410)<BR/>29 20 and 28 (470)<BR/>30 limit 29 to yr="2013 -Current" (10)</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-03" MODIFIED="2014-05-31 00:51:46 +1200" MODIFIED_BY="Irene OL Kwan" NO="3" NOTES="&lt;p&gt;Database: Ovid MEDLINE(R) In-Process &amp;amp; Other Non-Indexed Citations, Ovid MEDLINE(R) Daily and Ovid MEDLINE(R) &amp;lt;1946 to Present&amp;gt;&lt;br&gt;Search Strategy:&lt;br&gt;--------------------------------------------------------------------------------&lt;br&gt;1 Ovulation Induction/ (9334)&lt;br&gt;2 Ovarian Hyperstimulation Syndrome/ (1820)&lt;br&gt;3 Ovarian Follicle/ (15482)&lt;br&gt;4 Follicle Stimulating Hormone/ (33561)&lt;br&gt;5 Luteinizing Hormone/ (43567)&lt;br&gt;6 Gonadotropins/ (8559)&lt;br&gt;7 (ovulat$ adj5 (induct$ or stimulat$)).tw. (5383)&lt;br&gt;8 (ovar$ adj5 (induct$ or stimulat$ or follicle$)).tw. (16594)&lt;br&gt;9 ((ovar$ or ovulat$) adj5 (hyperstimulat$ or hyper stimulat$ or hyper-stimulat$)).tw. (4148)&lt;br&gt;10 gonadotrop?in$.tw. (54823)&lt;br&gt;11 (luteiniz$ adj5 hormone$).tw. (25679)&lt;br&gt;12 (stimulat$ adj5 (cycle$ or hormone$)).tw. (46698)&lt;br&gt;13 or/1-12 (148059)&lt;br&gt;14 exp Fertilization in Vitro/ (28877)&lt;br&gt;15 (IVF or in vitro fertili?ation or in-vitro fertili?ation or in-vitro-fertili?ation).tw. (25039)&lt;br&gt;16 Intracytoplasmic Sperm Injections/ (4885)&lt;br&gt;17 ((intracytoplasmic or intra-cytoplasmic) adj5 sperm inject$).tw. (5266)&lt;br&gt;18 ICSI.tw. (5731)&lt;br&gt;19 or/14-18 (37505)&lt;br&gt;20 13 and 19 (11236)&lt;br&gt;21 (ultrasound or ultrasonograph$ or ultra-sound or ultra-sonograph$).tw. (213860)&lt;br&gt;22 ((ovar$ or ovulat$) adj5 (monitor$ or scan$ or measur$)).tw. (4958)&lt;br&gt;23 exp Estradiol/ (78035)&lt;br&gt;24 ((oestrad$ or estrad$) adj5 (monitor$ or scan$ or measur$)).tw. (3466)&lt;br&gt;25 (hormon$ adj5 (measure$ or monitor$ or scan$)).tw. (12266)&lt;br&gt;26 exp Ultrasonography/ (247214)&lt;br&gt;27 echograph$.tw. (8587)&lt;br&gt;28 or/21-27 (471834)&lt;br&gt;29 20 and 28 (3469)&lt;br&gt;30 randomized controlled trial.pt. (388449)&lt;br&gt;31 controlled clinical trial.pt. (89795)&lt;br&gt;32 randomized.ab. (303425)&lt;br&gt;33 randomised.ab. (66704)&lt;br&gt;34 placebo.tw. (167340)&lt;br&gt;35 clinical trials as topic.sh. (175082)&lt;br&gt;36 randomly.ab. (214741)&lt;br&gt;37 trial.ti. (130862)&lt;br&gt;38 (crossover or cross-over or cross over).tw. (62723)&lt;br&gt;39 or/30-38 (973585)&lt;br&gt;40 exp animals/ not humans.sh. (4051544)&lt;br&gt;41 39 not 40 (899514)&lt;br&gt;42 29 and 41 (557)&lt;br&gt;43 2013$.ed. (775629)&lt;br&gt;44 42 and 43 (14)&lt;br&gt;&lt;/p&gt;" NOTES_MODIFIED="2014-05-31 00:51:46 +1200" NOTES_MODIFIED_BY="Irene OL Kwan">
<TITLE MODIFIED="2014-05-31 00:36:54 +1200" MODIFIED_BY="Irene OL Kwan">Ovid MEDLINE search strategy (20 May 2014)</TITLE>
<APPENDIX_BODY MODIFIED="2014-05-31 00:51:46 +1200" MODIFIED_BY="[Empty name]">
<P>Database: Ovid MEDLINE(R) In-Process &amp; Other Non-Indexed Citations, Ovid MEDLINE(R) Daily and Ovid MEDLINE(R) &lt;1946 to Present&gt;<BR/>Search Strategy:<BR/>--------------------------------------------------------------------------------<BR/>1 Ovulation Induction/ (8926)<BR/>2 Ovarian Hyperstimulation Syndrome/ (1736)<BR/>3 Ovarian Follicle/ (15163)<BR/>4 Follicle Stimulating Hormone/ (32964)<BR/>5 Luteinizing Hormone/ (42967)<BR/>6 Gonadotropins/ (8402)<BR/>7 (ovulat$ adj5 (induct$ or stimulat$)).tw. (5299)<BR/>8 (ovar$ adj5 (induct$ or stimulat$ or follicle$)).tw. (16264)<BR/>9 ((ovar$ or ovulat$) adj5 (hyperstimulat$ or hyper stimulat$ or hyper-stimulat$)).tw. (3965)<BR/>10 gonadotrop?in$.tw. (53846)<BR/>11 (luteiniz$ adj5 hormone$).tw. (25275)<BR/>12 (stimulat$ adj5 (cycle$ or hormone$)).tw. (45955)<BR/>13 or/1-12 (145856)<BR/>14 exp Fertilization in Vitro/ (27947)<BR/>15 (IVF or in vitro fertili?ation or in-vitro fertili?ation or in-vitro-fertili?ation).tw. (24620)<BR/>16 Intracytoplasmic Sperm Injections/ (4600)<BR/>17 ((intracytoplasmic or intra-cytoplasmic) adj5 sperm inject$).tw. (5141)<BR/>18 ICSI.tw. (5486)<BR/>19 or/14-18 (36686)<BR/>20 13 and 19 (10815)<BR/>21 (ultrasound or ultrasonograph$ or ultra-sound or ultra-sonograph$).tw. (216336)<BR/>22 ((ovar$ or ovulat$) adj5 (monitor$ or scan$ or measur$)).tw. (4931)<BR/>23 exp Estradiol/ (74460)<BR/>24 ((oestrad$ or estrad$) adj5 (monitor$ or scan$ or measur$)).tw. (3412)<BR/>25 (hormon$ adj5 (measure$ or monitor$ or scan$)).tw. (12149)<BR/>26 exp Ultrasonography/ (247866)<BR/>27 echograph$.tw. (8633)<BR/>28 or/21-27 (470968)<BR/>29 20 and 28 (3305)<BR/>30 randomized controlled trial.pt. (373788)<BR/>31 controlled clinical trial.pt. (88373)<BR/>32 randomized.ab. (293663)<BR/>33 randomised.ab. (58854)<BR/>34 placebo.tw. (158182)<BR/>35 clinical trials as topic.sh. (169943)<BR/>36 randomly.ab. (212697)<BR/>37 trial.ti. (126393)<BR/>38 (crossover or cross-over or cross over).tw. (60653)<BR/>39 or/30-38 (943680)<BR/>40 exp animals/ not humans.sh. (3939073)<BR/>41 39 not 40 (870261)<BR/>42 29 and 41 (511)<BR/>43 (201310$ or 201311$ or 201312$).ed. (232178)<BR/>44 2014$.ed. (381204)<BR/>45 2014$.dp. (372749)<BR/>46 43 or 44 or 45 (913311)<BR/>47 42 and 46 (13)<BR/>
</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-04" MODIFIED="2014-05-31 00:53:39 +1200" MODIFIED_BY="Irene OL Kwan" NO="4" NOTES="&lt;p&gt;Database: Embase &amp;lt;1980 to 2013 Week 41&amp;gt;&lt;br&gt;Search Strategy:&lt;br&gt;--------------------------------------------------------------------------------&lt;br&gt;1 Ovulation Induction/ (10804)&lt;br&gt;2 Ovarian Hyperstimulation Syndrome/ (6107)&lt;br&gt;3 Ovarian Follicle/ (13796)&lt;br&gt;4 Follicle Stimulating Hormone/ (43786)&lt;br&gt;5 Luteinizing Hormone/ (48206)&lt;br&gt;6 Gonadotropins/ (22102)&lt;br&gt;7 (ovulat$ adj5 (induct$ or stimulat$)).tw. (6392)&lt;br&gt;8 (ovar$ adj5 (induct$ or stimulat$ or follicle$)).tw. (19075)&lt;br&gt;9 ((ovar$ or ovulat$) adj5 (hyperstimulat$ or hyper stimulat$ or hyper-stimulat$)).tw. (5384)&lt;br&gt;10 gonadotrop?in$.tw. (56246)&lt;br&gt;11 (luteiniz$ adj5 hormone$).tw. (24044)&lt;br&gt;12 (stimulat$ adj5 (cycle$ or hormone$)).tw. (48408)&lt;br&gt;13 or/1-12 (165184)&lt;br&gt;14 exp Fertilization in Vitro/ (38133)&lt;br&gt;15 (IVF or in vitro fertili?ation or in-vitro fertili?ation or in-vitro-fertili?ation).tw. (33347)&lt;br&gt;16 exp Intracytoplasmic Sperm Injection/ (12083)&lt;br&gt;17 ((intracytoplasmic or intra-cytoplasmic) adj5 sperm inject$).tw. (6479)&lt;br&gt;18 ICSI.tw. (9210)&lt;br&gt;19 or/14-18 (52420)&lt;br&gt;20 13 and 19 (16736)&lt;br&gt;21 (ultrasound or ultrasonograph$ or ultra-sound or ultra-sonograph$).tw. (280397)&lt;br&gt;22 ((ovar$ or ovulat$) adj5 (monitor$ or scan$ or measur$)).tw. (5837)&lt;br&gt;23 ((oestrad$ or estrad$) adj5 (monitor$ or scan$ or measur$)).tw. (3729)&lt;br&gt;24 (hormon$ adj5 (measure$ or monitor$ or assay$)).tw. (17059)&lt;br&gt;25 exp ultrasound/ (92055)&lt;br&gt;26 exp echography/ (494865)&lt;br&gt;27 echograph$.tw. (11213)&lt;br&gt;28 (hormon$ adj5 (measure$ or monitor$ or scan$)).tw. (13480)&lt;br&gt;29 or/21-28 (666268)&lt;br&gt;30 20 and 29 (3113)&lt;br&gt;31 Clinical Trial/ (889001)&lt;br&gt;32 Randomized Controlled Trial/ (357811)&lt;br&gt;33 exp randomization/ (63609)&lt;br&gt;34 Single Blind Procedure/ (18340)&lt;br&gt;35 Double Blind Procedure/ (118100)&lt;br&gt;36 Crossover Procedure/ (38658)&lt;br&gt;37 Placebo/ (226879)&lt;br&gt;38 Randomi?ed controlled trial$.tw. (94914)&lt;br&gt;39 Rct.tw. (12713)&lt;br&gt;40 random allocation.tw. (1298)&lt;br&gt;41 randomly allocated.tw. (19750)&lt;br&gt;42 allocated randomly.tw. (1929)&lt;br&gt;43 (allocated adj2 random).tw. (735)&lt;br&gt;44 Single blind$.tw. (13963)&lt;br&gt;45 Double blind$.tw. (140818)&lt;br&gt;46 ((treble or triple) adj blind$).tw. (335)&lt;br&gt;47 placebo$.tw. (195922)&lt;br&gt;48 prospective study/ (251676)&lt;br&gt;49 or/31-48 (1380585)&lt;br&gt;50 case study/ (21625)&lt;br&gt;51 case report.tw. (253680)&lt;br&gt;52 abstract report/ or letter/ (888841)&lt;br&gt;53 or/50-52 (1158758)&lt;br&gt;54 49 not 53 (1343470)&lt;br&gt;55 30 and 54 (647)&lt;br&gt;56 2013$.em. (1276900)&lt;br&gt;57 55 and 56 (65)&lt;/p&gt;" NOTES_MODIFIED="2014-05-31 00:53:39 +1200" NOTES_MODIFIED_BY="Irene OL Kwan">
<TITLE MODIFIED="2014-05-31 00:35:13 +1200" MODIFIED_BY="Irene OL Kwan">EMBASE search strategy (20 May 2014)</TITLE>
<APPENDIX_BODY MODIFIED="2014-05-31 00:53:39 +1200" MODIFIED_BY="[Empty name]">
<P>Database: Embase &lt; 1980 to 2014 Week 20&gt;<BR/>Search Strategy:<BR/>--------------------------------------------------------------------------------<BR/>1 Ovulation Induction/ (10545)<BR/>2 Ovarian Hyperstimulation Syndrome/ (6330)<BR/>3 Ovarian Follicle/ (13554)<BR/>4 Follicle Stimulating Hormone/ (40096)<BR/>5 Luteinizing Hormone/ (47094)<BR/>6 Gonadotropins/ (21901)<BR/>7 (ovulat$ adj5 (induct$ or stimulat$)).tw. (6292)<BR/>8 (ovar$ adj5 (induct$ or stimulat$ or follicle$)).tw. (19113)<BR/>9 ((ovar$ or ovulat$) adj5 (hyperstimulat$ or hyper stimulat$ or hyper-stimulat$)).tw. (5426)<BR/>10 gonadotrop?in$.tw. (54983)<BR/>11 (luteiniz$ adj5 hormone$).tw. (23538)<BR/>12 (stimulat$ adj5 (cycle$ or hormone$)).tw. (47601)<BR/>13 or/1-12 (161565)<BR/>14 exp Fertilization in Vitro/ (38208)<BR/>15 (IVF or in vitro fertili?ation or in-vitro fertili?ation or in-vitro-fertili?ation).tw. (33773)<BR/>16 exp Intracytoplasmic Sperm Injection/ (12528)<BR/>17 ((intracytoplasmic or intra-cytoplasmic) adj5 sperm inject$).tw. (6555)<BR/>18 ICSI.tw. (9464)<BR/>19 or/14-18 (52926)<BR/>20 13 and 19 (16720)<BR/>21 (ultrasound or ultrasonograph$ or ultra-sound or ultra-sonograph$).tw. (287310)<BR/>22 ((ovar$ or ovulat$) adj5 (monitor$ or scan$ or measur$)).tw. (5859)<BR/>23 ((oestrad$ or estrad$) adj5 (monitor$ or scan$ or measur$)).tw. (3683)<BR/>24 (hormon$ adj5 (measure$ or monitor$ or assay$)).tw. (16839)<BR/>25 exp ultrasound/ (101105)<BR/>26 exp echography/ (501808)<BR/>27 echograph$.tw. (10048)<BR/>28 (hormon$ adj5 (measure$ or monitor$ or scan$)).tw. (13391)<BR/>29 or/21-28 (678508)<BR/>30 20 and 29 (3133)<BR/>31 Clinical Trial/ (830705)<BR/>32 Randomized Controlled Trial/ (341422)<BR/>33 exp randomization/ (61977)<BR/>34 Single Blind Procedure/ (18225)<BR/>35 Double Blind Procedure/ (113073)<BR/>36 Crossover Procedure/ (38825)<BR/>37 Placebo/ (238864)<BR/>38 Randomi?ed controlled trial$.tw. (97655)<BR/>39 Rct.tw. (13725)<BR/>40 random allocation.tw. (1297)<BR/>41 randomly allocated.tw. (20015)<BR/>42 allocated randomly.tw. (1916)<BR/>43 (allocated adj2 random).tw. (710)<BR/>44 Single blind$.tw. (14129)<BR/>45 Double blind$.tw. (139503)<BR/>46 ((treble or triple) adj blind$).tw. (361)<BR/>47 placebo$.tw. (195795)<BR/>48 prospective study/ (249423)<BR/>49 or/31-48 (1350956)<BR/>50 case study/ (25746)<BR/>51 case report.tw. (256378)<BR/>52 abstract report/ or letter/ (888025)<BR/>53 or/50-52 (1164600)<BR/>54 49 not 53 (1313533)<BR/>55 30 and 54 (645)<BR/>56 (201310$ or 201311$ or 201312$).em. (67090)<BR/>57 2014$.em. (694933)<BR/>58 2014$.dp. (41843)<BR/>59 56 or 57 or 58 (764192)<BR/>60 55 and 59 (20)</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-05" MODIFIED="2014-05-31 00:54:12 +1200" MODIFIED_BY="Irene OL Kwan" NO="5" NOTES="&lt;p&gt;Database: PsycINFO &amp;lt;1806 to October Week 3 2013&amp;gt;&lt;br&gt;Search Strategy:&lt;br&gt;--------------------------------------------------------------------------------&lt;br&gt;1 exp Reproductive Technology/ or exp Ovulation/ or exp Infertility/ (2801)&lt;br&gt;2 (ovulat$ adj5 (induct$ or stimulat$)).tw. (50)&lt;br&gt;3 (ovar$ adj5 (induct$ or stimulat$ or follicle$)).tw. (209)&lt;br&gt;4 ((ovar$ or ovulat$) adj5 (hyperstimulat$ or hyper stimulat$ or hyper-stimulat$)).tw. (9)&lt;br&gt;5 (IVF or in vitro fertili?ation or in-vitro fertili?ation or in-vitro-fertili?ation).tw. (590)&lt;br&gt;6 ((intracytoplasmic or intra-cytoplasmic) adj5 sperm inject$).tw. (36)&lt;br&gt;7 ICSI.tw. (41)&lt;br&gt;8 or/1-7 (3164)&lt;br&gt;9 (ultrasound or ultrasonograph$ or ultra-sound or ultra-sonograph$).tw. (2548)&lt;br&gt;10 ((ovar$ or ovulat$) adj5 (monitor$ or scan$ or measur$)).tw. (115)&lt;br&gt;11 ((oestrad$ or estrad$) adj5 (monitor$ or scan$ or measur$)).tw. (158)&lt;br&gt;12 (hormon$ adj5 (measure$ or monitor$ or scan$)).tw. (1068)&lt;br&gt;13 exp Ultrasound/ (940)&lt;br&gt;14 echograph$.tw. (48)&lt;br&gt;15 or/9-14 (4095)&lt;br&gt;16 8 and 15 (49)&lt;br&gt;17 limit 16 to yr=&amp;quot;2013&amp;quot; (4)&lt;/p&gt;" NOTES_MODIFIED="2014-05-31 00:54:12 +1200" NOTES_MODIFIED_BY="Irene OL Kwan">
<TITLE MODIFIED="2014-05-31 00:37:05 +1200" MODIFIED_BY="Irene OL Kwan">PsycINFO search strategy (20 May 2014)</TITLE>
<APPENDIX_BODY MODIFIED="2014-05-31 00:54:12 +1200" MODIFIED_BY="[Empty name]">
<P>Database: PsycINFO &lt;1806 to May Week 2 2014&gt;<BR/>Search Strategy:<BR/>--------------------------------------------------------------------------------<BR/>1 exp Reproductive Technology/ or exp Ovulation/ or exp Infertility/ (2907)<BR/>2 (ovulat$ adj5 (induct$ or stimulat$)).tw. (50)<BR/>3 (ovar$ adj5 (induct$ or stimulat$ or follicle$)).tw. (211)<BR/>4 ((ovar$ or ovulat$) adj5 (hyperstimulat$ or hyper stimulat$ or hyper-stimulat$)).tw. (9)<BR/>5 (IVF or in vitro fertili?ation or in-vitro fertili?ation or in-vitro-fertili?ation).tw. (613)<BR/>6 ((intracytoplasmic or intra-cytoplasmic) adj5 sperm inject$).tw. (37)<BR/>7 ICSI.tw. (44)<BR/>8 or/1-7 (3282)<BR/>9 (ultrasound or ultrasonograph$ or ultra-sound or ultra-sonograph$).tw. (2679)<BR/>10 ((ovar$ or ovulat$) adj5 (monitor$ or scan$ or measur$)).tw. (119)<BR/>11 ((oestrad$ or estrad$) adj5 (monitor$ or scan$ or measur$)).tw. (159)<BR/>12 (hormon$ adj5 (measure$ or monitor$ or scan$)).tw. (1100)<BR/>13 exp Ultrasound/ (983)<BR/>14 echograph$.tw. (50)<BR/>15 or/9-14 (4266)<BR/>16 8 and 15 (51)<BR/>17 random.tw. (40490)<BR/>18 control.tw. (314333)<BR/>19 double-blind.tw. (17824)<BR/>20 clinical trials/ (7555)<BR/>21 placebo/ (3760)<BR/>22 exp Treatment/ (578758)<BR/>23 or/17-22 (883642)<BR/>24 16 and 23 (21)<BR/>25 limit 24 to yr="2013 -Current" (2)</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-06" MODIFIED="2014-05-31 00:47:41 +1200" MODIFIED_BY="Irene OL Kwan" NO="6" NOTES="&lt;p&gt;&lt;b&gt;IOK972 CINAHL 21.10.13&lt;/b&gt;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;table rows=&quot;0&quot; cols=&quot;0&quot;&gt;&lt;tr&gt;&lt;td&gt;&lt;p&gt;&lt;b&gt;# &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p&gt;&lt;b&gt;Query &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p&gt;&lt;b&gt;Results &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;&lt;p&gt;S27&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p&gt;S14 AND S26&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p&gt;117&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;&lt;p&gt;S26&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p&gt;S22 AND S25&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p&gt;345&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;&lt;p&gt;S25&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p&gt;S23 OR S24&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p&gt;1,505&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;&lt;p&gt;S24&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p&gt;(MH &amp;quot;Ovarian Hyperstimulation Syndrome&amp;quot;) OR &amp;quot;ovarian hyperstimulation syndrome&amp;quot;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p&gt;202&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;&lt;p&gt;S23&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p&gt;TX ovulat*&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p&gt;1,373&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;&lt;p&gt;S22&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p&gt;S15 OR S16 OR S17 OR S18 OR S19 OR S20 OR S21&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p&gt;450,401&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;&lt;p&gt;S21&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p&gt;TX echograph*&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p&gt;173&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;&lt;p&gt;S20&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p&gt;TX Measur*&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p&gt;350,807&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;&lt;p&gt;S19&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p&gt;TX scanned&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p&gt;1,212&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;&lt;p&gt;S18&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p&gt;TX scanning&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p&gt;6,423&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;&lt;p&gt;S17&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p&gt;TX scan&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p&gt;12,299&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;&lt;p&gt;S16&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p&gt;TX monitor*&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p&gt;82,820&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;&lt;p&gt;S15&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p&gt;(MH &amp;quot;Ultrasonography, Prenatal&amp;quot;) OR (MH &amp;quot;Ultrasonography&amp;quot;) OR &amp;quot;ultrasound&amp;quot;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p&gt;31,069&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;&lt;p&gt;S14&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p&gt;S1 OR S2 or S3 or S4 OR S5 OR S6 OR S7 OR S8 OR S9 OR S10 OR S11 OR S12 OR S13&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p&gt;Display&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;&lt;p&gt;S13&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p&gt;TX allocat* random*&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p&gt;Display&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;&lt;p&gt;S12&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p&gt;(MH &amp;quot;Quantitative Studies&amp;quot;)&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p&gt;Display&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;&lt;p&gt;S11&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p&gt;(MH &amp;quot;Placebos&amp;quot;)&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p&gt;Display&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;&lt;p&gt;S10&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p&gt;TX placebo*&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p&gt;Display&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;&lt;p&gt;S9&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p&gt;TX random* allocat*&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p&gt;Display&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;&lt;p&gt;S8&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p&gt;(MH &amp;quot;Random Assignment&amp;quot;)&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p&gt;Display&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;&lt;p&gt;S7&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p&gt;TX randomi* control* trial*&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p&gt;Display&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;&lt;p&gt;S6&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p&gt;TX ( (singl* n1 blind*) or (singl* n1 mask*) ) or TX ( (doubl* n1 blind*) or (doubl* n1 mask*) ) or TX ( (tripl* n1 blind*) or (tripl* n1 mask*) ) or TX ( (trebl* n1 blind*) or (trebl* n1 mask*) )&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p&gt;Display&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;&lt;p&gt;S5&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p&gt;TX ( (trebl* n1 blind*) or (trebl* n1 mask*) )&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p&gt;Display&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;&lt;p&gt;S4&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p&gt;TX ( (trebl* n1 blind*) or (trebl* n1 mask*) )&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p&gt;Display&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;&lt;p&gt;S3&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p&gt;TX clinic* n1 trial*&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p&gt;Display&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;&lt;p&gt;S2&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p&gt;PT Clinical trial&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p&gt;Display&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;&lt;p&gt;S1&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p&gt;(MH &amp;quot;Clinical Trials+&amp;quot;)&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p&gt;Display&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p&gt;&lt;/p&gt;" NOTES_MODIFIED="2014-05-31 00:47:41 +1200" NOTES_MODIFIED_BY="Irene OL Kwan">
<TITLE MODIFIED="2014-05-31 00:38:04 +1200" MODIFIED_BY="Irene OL Kwan">CINAHL search strategy (20 May 2014)</TITLE>
<APPENDIX_BODY MODIFIED="2014-05-31 00:47:41 +1200" MODIFIED_BY="[Empty name]">
<P/>
<TABLE COLS="3" ROWS="28">
<TR>
<TD>
<P>
<B># </B>
</P>
</TD>
<TD>
<P>
<B>Query </B>
</P>
</TD>
<TD>
<P>
<B>Results </B>
</P>
</TD>
</TR>
<TR>
<TD>
<P>S27</P>
</TD>
<TD>
<P>S14 AND S26</P>
</TD>
<TD>
<P>117</P>
</TD>
</TR>
<TR>
<TD>
<P>S26</P>
</TD>
<TD>
<P>S22 AND S25</P>
</TD>
<TD>
<P>345</P>
</TD>
</TR>
<TR>
<TD>
<P>S25</P>
</TD>
<TD>
<P>S23 OR S24</P>
</TD>
<TD>
<P>1,505</P>
</TD>
</TR>
<TR>
<TD>
<P>S24</P>
</TD>
<TD>
<P>(MH "Ovarian Hyperstimulation Syndrome") OR "ovarian hyperstimulation syndrome"</P>
</TD>
<TD>
<P>202</P>
</TD>
</TR>
<TR>
<TD>
<P>S23</P>
</TD>
<TD>
<P>TX ovulat*</P>
</TD>
<TD>
<P>1,373</P>
</TD>
</TR>
<TR>
<TD>
<P>S22</P>
</TD>
<TD>
<P>S15 OR S16 OR S17 OR S18 OR S19 OR S20 OR S21</P>
</TD>
<TD>
<P>450,401</P>
</TD>
</TR>
<TR>
<TD>
<P>S21</P>
</TD>
<TD>
<P>TX echograph*</P>
</TD>
<TD>
<P>173</P>
</TD>
</TR>
<TR>
<TD>
<P>S20</P>
</TD>
<TD>
<P>TX Measur*</P>
</TD>
<TD>
<P>350,807</P>
</TD>
</TR>
<TR>
<TD>
<P>S19</P>
</TD>
<TD>
<P>TX scanned</P>
</TD>
<TD>
<P>1,212</P>
</TD>
</TR>
<TR>
<TD>
<P>S18</P>
</TD>
<TD>
<P>TX scanning</P>
</TD>
<TD>
<P>6,423</P>
</TD>
</TR>
<TR>
<TD>
<P>S17</P>
</TD>
<TD>
<P>TX scan</P>
</TD>
<TD>
<P>12,299</P>
</TD>
</TR>
<TR>
<TD>
<P>S16</P>
</TD>
<TD>
<P>TX monitor*</P>
</TD>
<TD>
<P>82,820</P>
</TD>
</TR>
<TR>
<TD>
<P>S15</P>
</TD>
<TD>
<P>(MH "Ultrasonography, Prenatal") OR (MH "Ultrasonography") OR "ultrasound"</P>
</TD>
<TD>
<P>31,069</P>
</TD>
</TR>
<TR>
<TD>
<P>S14</P>
</TD>
<TD>
<P>S1 OR S2 or S3 or S4 OR S5 OR S6 OR S7 OR S8 OR S9 OR S10 OR S11 OR S12 OR S13</P>
</TD>
<TD>
<P>Display</P>
</TD>
</TR>
<TR>
<TD>
<P>S13</P>
</TD>
<TD>
<P>TX allocat* random*</P>
</TD>
<TD>
<P>Display</P>
</TD>
</TR>
<TR>
<TD>
<P>S12</P>
</TD>
<TD>
<P>(MH "Quantitative Studies")</P>
</TD>
<TD>
<P>Display</P>
</TD>
</TR>
<TR>
<TD>
<P>S11</P>
</TD>
<TD>
<P>(MH "Placebos")</P>
</TD>
<TD>
<P>Display</P>
</TD>
</TR>
<TR>
<TD>
<P>S10</P>
</TD>
<TD>
<P>TX placebo*</P>
</TD>
<TD>
<P>Display</P>
</TD>
</TR>
<TR>
<TD>
<P>S9</P>
</TD>
<TD>
<P>TX random* allocat*</P>
</TD>
<TD>
<P>Display</P>
</TD>
</TR>
<TR>
<TD>
<P>S8</P>
</TD>
<TD>
<P>(MH "Random Assignment")</P>
</TD>
<TD>
<P>Display</P>
</TD>
</TR>
<TR>
<TD>
<P>S7</P>
</TD>
<TD>
<P>TX randomi* control* trial*</P>
</TD>
<TD>
<P>Display</P>
</TD>
</TR>
<TR>
<TD>
<P>S6</P>
</TD>
<TD>
<P>TX ( (singl* n1 blind*) or (singl* n1 mask*) ) or TX ( (doubl* n1 blind*) or (doubl* n1 mask*) ) or TX ( (tripl* n1 blind*) or (tripl* n1 mask*) ) or TX ( (trebl* n1 blind*) or (trebl* n1 mask*) )</P>
</TD>
<TD>
<P>Display</P>
</TD>
</TR>
<TR>
<TD>
<P>S5</P>
</TD>
<TD>
<P>TX ( (trebl* n1 blind*) or (trebl* n1 mask*) )</P>
</TD>
<TD>
<P>Display</P>
</TD>
</TR>
<TR>
<TD>
<P>S4</P>
</TD>
<TD>
<P>TX ( (trebl* n1 blind*) or (trebl* n1 mask*) )</P>
</TD>
<TD>
<P>Display</P>
</TD>
</TR>
<TR>
<TD>
<P>S3</P>
</TD>
<TD>
<P>TX clinic* n1 trial*</P>
</TD>
<TD>
<P>Display</P>
</TD>
</TR>
<TR>
<TD>
<P>S2</P>
</TD>
<TD>
<P>PT Clinical trial</P>
</TD>
<TD>
<P>Display</P>
</TD>
</TR>
<TR>
<TD>
<P>S1</P>
</TD>
<TD>
<P>(MH "Clinical Trials+")</P>
</TD>
<TD>
<P>Display</P>
</TD>
</TR>
</TABLE>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS>
<EXTENSION ID="FLOW_1" NAME="FIGURE" REVMAN_VERSION="5.1.0" TYPE="FLOWCHART">
<ALIAS ALIAS_ID="1">
<FLOWCHARTBOX TEXT="&lt;p&gt;6 studies included in quantitative synthesis (meta-analysis)&lt;/p&gt;" WIDTH="150">
<FLOWCHARTBOX TEXT="&lt;p&gt;6 studies included in qualitative synthesis&lt;/p&gt;" WIDTH="150">
<FLOWCHARTBOX TEXT="&lt;p&gt;2 studies already included in previous version of review (Kwan 2008)&lt;/p&gt;"/>
<FLOWCHARTBOX TEXT="&lt;p&gt;4 new studies included&lt;/p&gt;" WIDTH="150">
<FLOWCHARTBOX TEXT="&lt;p&gt;7 full-text articles assessed for eligibility&lt;/p&gt;" WIDTH="150">
<FLOWCHARTBOX TEXT="&lt;p&gt;1117 records screened&lt;/p&gt;" WIDTH="150">
<FLOWCHARTBOX TEXT="&lt;p&gt;1117 records identified through databases searching (April-May 2014)&lt;/p&gt;" WIDTH="180"/>
<OUT TEXT="&lt;p&gt;1110 records excluded&lt;/p&gt;" WIDTH="150"/>
</FLOWCHARTBOX>
<OUT TEXT="&lt;p&gt;3 records excluded for the following reasons:&lt;/p&gt;&lt;p&gt;1 = non-randomised trial&lt;/p&gt;&lt;p&gt;1 = quasi-randomised trial&lt;/p&gt;&lt;p&gt;1 = did not meet inclusion criteria&lt;/p&gt;" WIDTH="180"/>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</ALIAS>
</EXTENSION>
</EXTENSIONS>
</COCHRANE_REVIEW>